| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Nervous System |
Recent Updates
Recently added Catalysts
Quantum Biopharma Ltd.$3.31
-0.16 (-4.69%)
D 39Pipeline Score Fair Value Biotech · Clinical
Market Cap
53.86 M
EPS
-8.19
P/E Ratio
-
Value Trade
1.83 M
36.28 %
Week
161.76 %
1 Month
148.39 %
3 Month
49.03 %
6 Month
-91.69 %
5 Year
-97.76 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
115.80 K
52 Week Range
2.07 - 38.25
% held by Insiders
11.02 %
% held by Institutions
3.99 %
Enterprise Value
42.65 M
Total Shares
3.82 M
Short %
10.12 %
Float Shares
3.54 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Quantum Biopharma Ltd.
337Total events
8Upcoming
68Tier-1 (high impact)
2020 – 2027Coverage
Upcoming catalysts 8
Event history 329
Jun 1, 2026
◆Management ChangeCorporate
Dr. Lakshmi P. Kotra resigned as director and from all positions at Quantum Biopharma
May 28, 2026
▼Clinical Hold PlacedLucid-21IND
FDA placed IND for Lucid-21-302 on clinical hold
multiple sclerosissource ↗
May 18, 2026
▲Enrollment MilestoneTrial
Patient enrollment reached halfway mark in imaging study with MGH
multiple sclerosissource ↗
May 7, 2026
May 7, 2026
▲Partnership / LicenseLucid-MSCorporate
Binding LOI signed with Allucent for Phase 2 trial
multiple sclerosissource ↗
May 7, 2026
●Management ChangeCorporate
Appointment of Dr. Salvatore Napoli as principal investigator for Lucid-MS Phase 2 trial
May 7, 2026
▲IP Litigation RulingIP / Competition
Court ruled against CIBC and RBC motion to dismiss lawsuit
May 2026
●Enrollment MilestoneTrial
PET imaging study reached halfway point in patient enrollment
multiple sclerosissource ↗
Apr 27, 2026
Apr 22, 2026
Q2 2026
●Trial InitiationLucid-MSTrial
Planned Phase 2 trial initiation for Lucid-MS
multiple sclerosissource ↗
Q2 2026
Drug Pipeline Intelligence
D39
Pipeline Score $125M
Pipeline ValueFair Value
Valuation Signal3
Drugs Scored2.3x
rNPV / MCap Top 55%
Micro Cap (rank 411 of 911)
Percentile RankQuantum Biopharma Ltd. faces pipeline headwinds (39/100), with $1.9B risk-adjusted pipeline value, led by Firibastat in Hypertension (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Firibastat Small molecule | Hypertension | Phase 3 | NCT04277884 | 48% | $951M | COMPLETED | 515 | - | - | Sep 20, 2022 | - | Oct 20, 2022 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Lucid-MS | multiple sclerosis | — | 2026-05-18 | Preliminary analyses indicate robust signal in acute MS lesions and potential sensitivity to gray matter lesions. Read More | Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital Read More | |
Lucid-MS | multiple sclerosis | — | 2026-05-18 | Preliminary analyses indicate robust signal in acute MS lesions and potential sensitivity to gray matter lesions. Read More | Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital Read More | |
Lucid-MS | multiple sclerosis | — | 2026-05-18 | Preliminary analyses indicate robust signal in acute MS lesions and potential sensitivity to gray matter lesions. Read More | Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in QNTM
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
QNTM Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
QNTMQuantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy
Quantum BioPharma Ltd. is developing Lucid-MS, a patented therapy aimed at treating multiple sclerosis by directly targeting the myelin sheath. Currently, there are no cures for MS, and existing treatments can only slow its progression. The company is preparing to advance Lucid-MS into phase 2 clinical trials, marking a significant step in its development.
Read more →QNTMThe Quest to Repair What Multiple Sclerosis Takes Away
Quantum BioPharma is advancing Lucid-MS, a novel drug candidate aimed at treating multiple sclerosis (MS) by directly targeting the myelin sheath. Currently preparing for phase 2 clinical trials, Lucid-MS has shown promise in preclinical studies, demonstrating the potential to protect myelin from degradation. This innovative approach could represent a significant breakthrough in MS treatment, addressing a critical unmet need in the market.
Read more →QNTM▲ +5.2%on this newsshared move
Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach
Quantum BioPharma Ltd. is advancing Lucid-MS, a patented drug candidate aimed at treating multiple sclerosis (MS) by targeting the myelin sheath. This innovative approach seeks to address a significant unmet need in MS treatment, as current therapies can only slow disease progression. The company is preparing to initiate phase 2 clinical trials for Lucid-MS.
Read more →QNTMNovel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
Quantum BioPharma is advancing Lucid-MS, a first-in-class drug candidate targeting the myelin sheath in multiple sclerosis (MS). Unlike existing treatments that modulate the immune system, Lucid-MS aims to prevent and potentially reverse myelin degradation. The company is preparing to enter phase 2 clinical trials after successful phase 1 results, highlighting a promising new approach to treating MS.
Read more →QNTMQuantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns
Quantum BioPharma Ltd. has signed a six-month agreement with Stocks.news for investor relations and marketing services, starting June 8, 2026. The deal, valued at $250,000, aims to enhance the company's visibility and engagement with potential investors. The agency will provide various services, including media distribution and lead generation campaigns.
Read more →QNTMTHIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS
Quantum BioPharma has received a clinical hold notice from the FDA regarding its drug candidate, Lucid-21-302 (Lucid-MS), for treating multiple sclerosis. The company is working closely with the FDA to address the agency's concerns, which they believe are manageable. As a consequence, Quantum has retracted its previously stated timelines for FDA review and upcoming trials. Moreover, the resignation of Dr. Lakshmi P. Kotra from his directorial role could affect the company’s governance structure as they navigate these challenges.
Read more →QNTM▼ -23.5%on this news· ran to -35% by day 3shared move
Quantum BioPharma Provides Corporate Update
Quantum BioPharma Ltd. has announced an update on its investigational drug, Lucid-MS, for multiple sclerosis treatment. Recently, the FDA placed the application on clinical hold, requesting more information before progressing. The company is reviewing these comments and plans to submit a response, believing the issues are addressable. Additionally, the company has withdrawn previous timelines regarding FDA review and trial initiation. Dr. Lakshmi P. Kotra has resigned from his directorship but will remain a senior clinical advisor.
Read more →QNTM▼ -7.9%on this news
Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital
Quantum BioPharma has achieved a significant milestone in its imaging study with Massachusetts General Hospital, reaching halfway in patient enrollment. Preliminary results indicate the PET imaging technique shows promise in assessing demyelination in multiple sclerosis patients. This advancement could transform treatment monitoring and enhance the evaluation of Quantum's investigational candidate, Lucid-MS.
Read more →QNTM▼ -5.1%on this news
Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026
Quantum BioPharma Ltd. reported strong financial results for Q1 2026, with liquidity more than doubling to US$11.2 million. The company achieved a significant reduction in cash burn and submitted an IND application for its MS drug candidate, Lucid-MS, to the FDA. Additionally, Quantum is pursuing a lawsuit against CIBC and RBC regarding alleged stock market manipulation.
Read more →QNTMQuantum Biopharma Ltd. (formerly, FSD Pharma Inc.) Condensed consolidated interim financial statements For the three months ended
Quantum Biopharma Ltd. reported its financial results for the three months ending March 31, 2026. The company faced a significant net loss of $13,753,564, compared to a loss of $8,739,881 for the same period in 2025. Operating expenses were reported at $2,966,305, which slightly decreased year-over-year but contributed to the ongoing financial challenges. The company's accumulated deficit continues to rise, reflecting its ongoing struggles within its business model and market environment.
Read more →QNTMQuantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant
Quantum BioPharma announced the appointment of Richard Buzbuzian as CEO of Unbuzzd Wellness Inc. to lead the commercialization of its clinically validated hangover remedy, unbuzzd. This appointment is part of a strategy to capitalize on the growing functional beverage market, projected to reach $198 billion by 2026. The company aims to expand its product's availability starting in South Florida and Texas while also planning for a stock exchange listing. Unbuzzd stands out in the wellness sector due to its peer-reviewed clinical study that supports its efficacy in alcohol metabolism and hangover symptom relief.
Read more →QNTM▼ -9.8%on this news
Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied
Quantum BioPharma Ltd. announced a court ruling in its favor regarding a lawsuit against CIBC World Markets and RBC Dominion Securities. The U.S. District Court for the Southern District of New York denied the defendants' joint motion to dismiss the case, which accuses them of market manipulation through 'spoofing' techniques. The allegations pertain to actions taken between January 1, 2020, and August 15, 2024, which violated SEC regulations. This ruling allows Quantum BioPharma to continue pursuing its claims in court.
Read more →QNTM▼ -8.7%on this news· ran to -20% by day 3shared move
Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis
Quantum BioPharma has submitted an Investigational New Drug application to the FDA for its drug candidate Lucid-MS, aimed at treating multiple sclerosis. This submission marks a significant step in the company's clinical development pipeline and reflects its commitment to innovative treatments. The planned Phase 2 trial will assess the drug's efficacy and safety, building on favorable results from earlier trials.
Read more →QNTM▼ -10.3%on this newsshared move
Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis
Quantum BioPharma has entered a binding Letter of Intent with Allucent to conduct a Phase 2 clinical trial for Lucid-MS, aimed at treating multiple sclerosis. This partnership marks a significant milestone in Quantum's clinical development, focusing on neuroprotection rather than immune modulation. The trial is expected to begin in Q2 2026, pending regulatory approvals.
Read more →QNTM▲ +24.5%on this newsshared move
Quantum Biopharma’s 2025 Audited Year End Financial Results Maintain ‘No Going Concern’ Status
Quantum BioPharma Ltd. reported its audited financial results for 2025, highlighting a strong cash position and reduced operating expenses. The company completed Phase 1 trials for its multiple sclerosis drug candidate, Lucid-MS, showing no toxicity. Additionally, it published positive results for its dietary supplement, unbuzzd, in a peer-reviewed journal. The company is preparing for a Phase 2 trial and has secured a product license for Qlarity from Health Canada.
Read more →QNTM▲ +24.5%on this newsshared move
Quantum Biopharma Provides Corporate Update
Quantum BioPharma Ltd. announced the grant of 35,000 stock options to employees and consultants, with immediate vesting and a five-year exercise period at CA$6.50. This move aligns with the company's strategy to build a portfolio of innovative biotech solutions, particularly for neurodegenerative and metabolic disorders. Additionally, the company retains a significant stake in Unbuzzd Wellness Inc., which is expected to generate royalty payments from sales. The update reflects Quantum BioPharma's ongoing commitment to advancing its therapeutic offerings.
Read more →QNTM▼ -12%on this newsshared move
Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis
Quantum BioPharma has appointed Dr. Salvatore Napoli as the Principal Investigator for its upcoming Phase 2 clinical trial of Lucid-21-302 (Lucid-MS) aimed at treating Multiple Sclerosis. The trial will assess the efficacy and safety of Lucid-MS, a novel therapy designed to prevent demyelination. The company plans to submit an IND application to the FDA soon.
Read more →QNTM▲ +38.4%on this news· ran to +111% by day 1shared move
Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd
Quantum BioPharma announced the publication of a peer-reviewed clinical trial for its dietary supplement, unbuzzd, which demonstrated significant efficacy in reducing blood alcohol concentration and alleviating symptoms of intoxication and hangover. The trial involved healthy participants and showed statistically significant improvements in alertness and physiological responses. The findings validate unbuzzd's role as a responsible aid for alcohol metabolism.
Read more →QNTM▼ -5.1%on this news· ran to +84% by day 3shared move
Quantum Biopharma Announces Closing of Initial Tranche of Private Placement Offering
Quantum BioPharma Ltd. has announced the successful closure of the initial tranche of its private placement offering, raising $3,750,000 to support business development and working capital. Additionally, the company has executed a Debt Settlement by issuing Class B Shares, which helped settle approximately $1.1 million in debt. There are concerns surrounding related party transactions due to a director's participation and the lack of a material change report on this matter, which could raise governance issues. The company relies on exemptions under relevant regulations for these transactions.
Read more →QNTM▼ -11.5%on this news· ran to -25% by day 3
Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS)
Quantum BioPharma has successfully completed the oral dosing of its drug candidate Lucid-21-302 (Lucid-MS) in 180-day toxicity and toxicokinetic studies. This milestone is pivotal for supporting the upcoming Investigational New Drug (IND) application with the US FDA and planning a Phase 2 trial for treating multiple sclerosis. Company executives expressed excitement about the drug's potential to inhibit demyelination and progress in the treatment of MS.
Read more →QNTM▲ +20.2%on this newsshared move
World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares
Quantum BioPharma shareholder Paul Durkacz has initiated a class action lawsuit against CIBC and RBC, alleging stock market manipulation that harmed investors between January 2021 and October 2025. The company intends to seek lead plaintiff status to protect its shareholders. This legal action raises concerns regarding the company's reputation and financial health.
Read more →QNTM▲ +20.2%on this newsshared move
Quantum BioPharma Ltd. Provides Corporate Update TORONTO
Quantum BioPharma Ltd. announced an at-the-market offering agreement allowing it to raise up to $17.24 million through the sale of Class B Subordinate Voting Shares. The proceeds from the offering are intended for general corporate purposes and working capital. The company is focused on developing treatments for neurodegenerative and metabolic disorders, with a lead candidate aimed at addressing multiple sclerosis. However, the development efforts are at an early stage, carrying inherent risks and uncertainties in terms of product advancement and regulatory approvals.
Read more →QNTM▼ -7.3%on this news· ran to -18% by day 3
Quantum BioPharma Announces Closing of Private Placement & Provides Corporate Update
Quantum BioPharma has announced the successful closing of a private placement, which is expected to bolster its financial position. The company also provided a corporate update, highlighting its ongoing efforts and future plans. This move is seen as a positive step towards strengthening its operations and advancing its projects.
Read more →QNTM▼ -11.6%on this news
Investigative News Program W5 Airs Final Segment on USD $700 Million Stock Market Manipulation Lawsuit of Quantum Biopharma Involving CIBC and RBC
Quantum BioPharma Ltd. has announced the airing of the final segment of a three-part investigative series by CTV News' W5, focusing on the company's allegations of stock market manipulation. The series highlights a USD $700 million lawsuit against CIBC and RBC, addressing the illegal practice of stock spoofing. CEO Zeeshan Saeed reaffirmed the company's commitment to its shareholders and called for action against market manipulation.
Read more →QNTM▼ -19.2%on this newsshared move
REPEAT: Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada’s Largest Banks, CIBC and RBC
Quantum BioPharma Ltd. is featured in a W5 investigative series addressing allegations of stock market manipulation, particularly stock spoofing, against CIBC and RBC. The company is pursuing a $700 million lawsuit, claiming that these banks facilitated illegal trading practices that affected their stock price. CEO Zeeshan Saeed emphasizes the importance of this investigation for protecting investors and highlights the potential of their drug, Lucid-MS, in treating multiple sclerosis.
Read more →QNTM▲ +31.1%on this newsshared move
Quantum Biopharma’s USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5
Quantum BioPharma Ltd. is featured in a three-part investigative series by CTV News' W5, focusing on the company's allegations of stock market manipulation. The series highlights a USD $700 million lawsuit against CIBC and RBC, stemming from claims of illegal 'stock spoofing.' CEO Zeeshan Saeed emphasizes the importance of this investigation for retail investors and the potential of their drug, Lucid-MS, in treating multiple sclerosis.
Read more →QNTMQuantum Biopharma Reports Strong Third Quarter Results Maintaining ‘No Going Concern’ Status with Cash Runway Extending Beyond March 2027, and $572,000 USD Gains in Crypto Portfolio
Quantum BioPharma Ltd. reported strong financial results for Q3 2025, showcasing a significant increase in shareholder equity and a reduction in liabilities. The company maintains a 'no going concern' status, ensuring operations can continue beyond March 2027. Notably, progress continues on its multiple sclerosis drug, Lucid-MS, and the company has realized gains from its cryptocurrency investments.
Read more →QNTMQuantum Biopharma Ltd. (formerly, FSD Pharma Inc.) Condensed consolidated interim financial statements For the three and nine months ended
Quantum Biopharma Ltd. (formerly FSD Pharma Inc.) released its consolidated financial statements for the three and nine months ending September 30, 2025. The company reported a substantial net loss of over $23 million for the nine-month period, significantly higher than the prior year's loss. Total assets also saw a decline from December 31, 2024, which raises concerns about the company's financial health. Additionally, cash used in operating activities has increased, suggesting ongoing operational challenges.
Read more →QNTMQuantum BioPharma Ltd. Provides Corporate Update
Quantum BioPharma Ltd. has announced an at-the-market offering of Class B Subordinate Voting Shares, with a potential aggregate offering price of up to $21.225 million. The funds raised will support clinical studies, research and development, and general corporate purposes. The offering will be conducted through H.C. Wainwright & Co., LLC, with sales made at prevailing market prices.
Read more →QNTMFiled by newsfilecorp.com Quantum BioPharma to Present at Global Growth and Investment Conference Presented by ArcStone Securities and Investments and Kingswood US TORONTO, ON / ACCESSWIRE /
Quantum BioPharma Ltd. will present at the ArcStone-Kingswood Growth Summit in Toronto on September 26, 2024. Jason Sawyer, Head of Finance and Mergers and Acquisitions, will represent the company and engage in discussions about its growth potential. This event features multiple companies and sponsors, aiming to create value for investors. Quantum BioPharma focuses on innovative biopharmaceutical solutions, including the development of its lead compound, Lucid-MS, targeting neurodegenerative disorders.
Read more →QNTMFiled by newsfilecorp.com
The Canadian Depository for Securities has received the Notice of Record and Meeting Dates for QNTM's upcoming Annual General & Special Meeting. Scheduled for July 22, 2024, the meeting will involve registered and beneficial shareholders. The record date for voting is set for June 12, 2024, ensuring that interested parties are informed and able to participate.
Read more →QNTMFiled by newsfilecorp.com FORM 51-102F3 MATERIAL CHANGE REPORT Item 1: Name and Address of Company FSD Pharma Inc. (" FSD " or the " Company ") 199 Bay St., Suite 4000 Toronto, ON M5L 1A9 Item 2: Date of Material Change
FSD Pharma Inc. has announced the appointment of Dr. Sanjiv Chopra to its board of directors, replacing Nitin Kaushal who has resigned. The company has also retained multiple firms, including SBS Intl Group LLC, Draper, Inc., and Carriage House Capital, Corp., for a 12-month term to enhance its market presence and shareholder communications. Each firm will be compensated with stock options as part of their engagement agreements. This strategic move aims to bolster corporate governance and improve investor relations.
Read more →QNTMFiled by newsfilecorp.com FSD Pharma Announces Dr. Sanjiv Chopra is elected to FSD Pharma Board of Directors and Corporate Updates TORONTO
FSD Pharma has appointed Dr. Sanjiv Chopra to its board of directors, replacing Nitin Kaushal, who has resigned. Dr. Chopra brings significant expertise from his tenure at Harvard Medical School and a distinguished career in medicine. The company is also enhancing its market awareness through new partnerships while continuing development in neurodegenerative and metabolic disorder treatment innovations. This strategic move aims to bolster FSD Pharma's prospects for future growth.
Read more →QNTMFiled by newsfilecorp.com FSD Pharma Announces Filing of Year-End 2023 Results TORONTO, ON /
FSD Pharma Inc. announced the filing of their year-end 2023 financial results, providing insights into their operations and strategies. The company is focused on developing innovative biotech solutions for neurodegenerative conditions and substance misuse, particularly through their subsidiary, Lucid Psycheceuticals. Key developments include their lead compound, Lucid-MS, which has demonstrated potential in preclinical studies. However, the company emphasizes the inherent risks and uncertainties in drug development that could impact future progress.
Read more →QNTM▲ +6%on this newsshared move
Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar for its Disruptive Beverage Innovation that Speeds Alcohol Metabolism, Reduces Symptoms of Intoxication
Quantum BioPharma's licensee, Unbuzzd Wellness, is set to host a webinar on October 30, 2025, to discuss their innovative beverage designed to speed up alcohol metabolism and reduce hangover symptoms. The webinar will feature key company leaders and provide insights into investment opportunities, aiming to raise up to $5 million. Quantum BioPharma shareholders will not face dilution from this offering.
Read more →QNTMQuantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend
Quantum BioPharma Ltd. has announced the expiration of 53,147 warrants held by hedge funds, marking the end of a previous financing arrangement. The company reiterated October 27, 2025, as the record date for distributing contingent value rights (CVRs) to its Class B Subordinate Voting Shareholders. These CVRs are linked to potential financial recoveries from ongoing litigation against certain financial institutions, although there is no assurance of any proceeds.
Read more →QNTM▲ +5.3%on this news
Quantum BioPharma Ltd. Responds to Vague and Misleading Allegations by The Schall Law Firm and DJS Law Group
Quantum BioPharma Ltd. has issued a formal response to allegations made by The Schall Law Firm and DJS Law Group regarding potential securities law violations. The company refutes these claims as vague and lacking substantiation, asserting they are designed to provoke concern among shareholders. Quantum BioPharma is reviewing the conduct of the law firms involved and plans to take appropriate action.
Read more →QNTM▼ -8.2%on this news
Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock
Quantum BioPharma Ltd. has announced a public whistleblower policy offering up to USD $7 million for verifiable proof of stock manipulation. This initiative aims to support the company's ongoing lawsuit against major financial institutions accused of manipulating its stock price through illegal tactics. The company emphasizes confidentiality and encourages individuals with information to come forward to help restore market integrity.
Read more →QNTMQuantum BioPharma Announces the Record Date for the Distribution of a Special Dividend of Contingent Value Rights (CVRs) Tied to the Future Litigation Settlement Proceeds of its USD $700 Million+ Case
Quantum BioPharma has set October 27, 2025, as the record date for distributing contingent value rights (CVRs) to its Class B shareholders. These CVRs will allow holders to receive a portion of the net proceeds from a legal case alleging stock price manipulation, which seeks over $700 million in damages. However, there is no assurance that any payments will be made under the CVRs, as they depend on the success of the litigation.
Read more →QNTM▲ +9.5%on this newsshared move
Quantum BioPharma Receives Final Reports for Two Key Studies of its Potential Breakthrough Drug for Multiple Sclerosis, Moving Closer to Phase 2 Clinical Trial
Quantum BioPharma has received final reports for two key studies related to its drug Lucid-MS, aimed at treating Multiple Sclerosis. These reports will support an Investigational New Drug application to the US FDA for a Phase 2 clinical trial. The company expresses optimism about Lucid-MS's potential as a first-in-class treatment.
Read more →QNTMQuantum BioPharma Welcomes World-Renowned Multiple Sclerosis Expert Dr. Jack Antel as Clinical Development Advisor For Lucid-MS Trials
Quantum BioPharma has appointed Dr. Jack Antel as a clinical development advisor for its Lucid-MS trials. Dr. Antel, a prominent expert in multiple sclerosis, will guide the clinical development and efficacy trial design for the investigational drug Lucid-MS. His involvement is expected to significantly advance the program towards a Phase 2 clinical trial.
Read more →QNTMQuantum BioPharma Ltd. Announces Results of Annual General and Special Meeting of Shareholders
Quantum BioPharma Ltd. held its annual general and special meeting on September 26, 2025, where shareholders elected all nominated directors and re-appointed MNP LLP as the company's auditor. Additionally, shareholders authorized the board to issue up to 56 additional Class A multiple voting shares. The meeting reflects strong shareholder engagement and support for the company's strategic direction.
Read more →QNTM▼ -6.7%on this newsshared move
Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar and Q&A Session on Wednesday, October 1, 2025
Quantum BioPharma Ltd. (NASDAQ: QNTM) announced that its licensee, Unbuzzd Wellness Inc., will host an Investor Webinar on October 1, 2025. The event will focus on Unbuzzd, a beverage designed to accelerate alcohol metabolism and reduce hangover symptoms, highlighting its recent clinical trial successes. Key leadership from Unbuzzd will present this investment opportunity, which includes a Reg D 506(c) offering aiming to raise up to $5 million without diluting Quantum BioPharma shareholders. The company's innovative product, scientifically proven to alleviate alcohol-related impairments, aims to attract a diverse range of investors.
Read more →QNTM▲ +7.6%on this news
Quantum BioPharma Licensee Unbuzzd Wellness to Host Investor Webinar on September 16, 2025 at 1:30 PM PT
Quantum BioPharma announced that its licensee, Unbuzzd Wellness Inc., will host an investor webinar on September 16, 2025. During the webinar, executives will discuss investment opportunities related to their innovative beverage designed to accelerate alcohol metabolism and reduce hangover symptoms. The product's effectiveness has been demonstrated in a recent clinical trial, showing significant improvements in cognitive performance and reduced impairment. The webinar aims to attract current and potential investors to support Unbuzzd's expansion strategy.
Read more →QNTMQuantum BioPharma Announces Corporate Updates
Quantum BioPharma Ltd. announced key corporate updates including the settlement of debt through conversion to shares and the granting of restricted stock units to Clinical Advisors. The RSUs are tied to advancing regulatory approvals for their lead compound, Lucid-MS, which targets neurodegenerative disorders. There was also a change in the Advisory Board with the termination of Kevin Malone. Quantum continues to focus on both innovative drug development and strategic investments.
Read more →QNTM▼ -10.1%on this news· ran to -23% by day 3
Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial
Quantum BioPharma Ltd. has entered into an agreement with a contract development and manufacturing organization to produce an oral formulation of its drug Lucid-MS. This formulation is intended for use in the company's upcoming Phase 2 clinical trial aimed at treating multiple sclerosis (MS). Previous research indicates that Lucid-MS can help restore mobility in animal models. The drug is recognized as a first-in-class compound that targets the underlying issues of MS by preventing demyelination.
Read more →QNTM▲ +12.3%on this newsshared move
Quantum BioPharma Announces Very Promising Results from the Massachusetts General Hospital Scientists on the Novel Positron Emission Tomography (PET) Tracer Used to Detect and Monitor Demyelination in Multiple Sclerosis Patients
Quantum BioPharma has announced promising results from a joint study with Massachusetts General Hospital on a novel PET tracer, [18F]3F4AP, which is capable of detecting differences in lesions in multiple sclerosis patients. This tracer's ability to identify lesions not visible through traditional MRI indicates its potential as a crucial biomarker for monitoring myelin integrity. The findings may significantly advance the evaluation of Quantum's investigational drug, Lucid-21-302, aimed at protecting myelin sheaths in MS. The study was funded by the NIH and published in a reputable medical journal.
Read more →QNTMQuantum Biopharma Reports Strong Second Quarter with Increased Current and Total Assets, Conversion of all Debentures into Equity, Continued Exclusion of Going Concern, Tripling of Share Price during Quarter, over $500,000 USD Gain in Crypto Assets as of date of filing, and Near Elimination of Debt
Quantum BioPharma Ltd. reported strong financial results for Q2 2025, with increased current assets totaling $10.3 million and total assets of $15.3 million. The company successfully converted all debentures into equity, eliminating debt liabilities, and has shown significant growth in cryptocurrency reserves. Additionally, the company's multiple sclerosis drug, Lucid-MS, has completed toxicity studies with no adverse effects reported. The company is also pursuing advancements for its product unbuzzd, with plans for an Initial Public Offering in the future.
Read more →QNTMQuantum Biopharma Ltd. (formerly, FSD Pharma Inc.) Condensed consolidated interim financial statements For the three and six months ended
Quantum Biopharma Ltd., formerly known as FSD Pharma Inc., released its condensed consolidated interim financial statements for the three and six months ending June 30, 2025. The company reported significant losses, including a net loss of $18.5 million for the six-month period and an increase in total liabilities compared to previous periods. The financial positions show a notable decrease in cash reserves and a decline in total assets, raising concerns about the company’s financial health and sustainability going forward.
Read more →QNTM▼ -11.6%on this newsshared move
Quantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS)
Quantum BioPharma Ltd. announced that its clinical study report for the Phase 1 Multiple Ascending Dose trial of the experimental drug Lucid-MS revealed no safety or tolerability issues among healthy participants. This first-in-class compound aims to address multiple sclerosis through a novel mechanism that prevents demyelination. The company is now gearing up for human efficacy trials in patients with MS, marking a significant step forward in their clinical development efforts.
Read more →QNTM▲ +17.3%on this newsshared move
Quantum BioPharma Files Reply and Provides Update on Court Case Seeking Damages Against CIBC, RBC and Others in Excess of $700,000,000 USD for Possible Stock Price Manipulation/Spoofing
Quantum BioPharma Ltd. has filed a memorandum opposing the dismissal of its lawsuit in the Southern District of New York against CIBC and RBC for alleged stock price manipulation through spoofing. The lawsuit claims damages exceeding $700 million for actions purportedly taken between January 2020 and August 2024 that negatively impacted its stock price. Quantum BioPharma is leveraging contingently-based legal representation, which mitigates financial strain as it seeks justice. This case stands to reveal more details about potential misconduct in the financial sector related to its shares.
Read more →QNTMQuantum BioPharma Licensee Unbuzzd Wellness Inc. Commences Reg D Capital Raise Campaign to Fund Growth and Possible IPO
Quantum BioPharma Ltd. (QNTM) announced that its licensee, Unbuzzd Wellness Inc., has initiated a Regulation D 506(c) offering aiming to raise up to $5 million for growth and a possible IPO. Unbuzzd is known for its innovative beverage that accelerates alcohol metabolism and alleviates hangover symptoms. Importantly, Quantum BioPharma's anti-dilution provisions ensure that shareholders will not be impacted by this capital raise. The offering allows for investments from both traditional and cryptocurrency sources.
Read more →QNTM▼ -7.8%on this news
Quantum BioPharma Makes Strategic Investment in GameStop Corp.
Quantum BioPharma Ltd. has made a strategic investment in 2,000 shares of GameStop Corp. as part of its efforts to enhance shareholder value and combat market manipulation. This investment aligns with the company's ongoing initiatives, including legal actions against firms accused of stock price manipulation and the advancement of its Multiple Sclerosis treatment. Board Advisor Kevin Malone emphasized the perceived value of GameStop, noting its strong cash position. As Quantum BioPharma continues to manage its assets, the company's focus remains on developing innovative therapies and navigating market challenges.
Read more →QNTM▲ +5.1%on this news
Quantum BioPharma Submits its Candidate Breakthrough Patented Drug for Multiple Sclerosis for Fast-Track Program in the United Kingdom
Quantum BioPharma has submitted its breakthrough drug Lucid-21-302 for multiple sclerosis to the UK's Innovative Licensing and Access Pathway. This submission aims to accelerate the development and approval processes for this first-in-class treatment. The ILAP program facilitates collaboration among various healthcare stakeholders to expedite access to new medicines. Company representatives expressed optimism about the potential impacts of this submission on regulatory approvals and patient access.
Read more →QNTMQuantum BioPharma Announces Private Placement of 12 Class A Multiple Voting Shares at a Price of $50 Per Share
Quantum BioPharma Ltd. announced the completion of a non-brokered private placement of class A multiple voting shares at $50 each, potentially raising up to $600. The offering is expected to be fully subscribed by existing holders and is intended for general working capital purposes. The participation of insiders in this transaction may elicit concerns regarding conflicts of interest, while the issued securities remain subject to a statutory hold period. These developments indicate continued confidence in the company's growth strategy and operations.
Read more →QNTM▼ -13.3%on this newsshared move
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Launches $5 Million Reg D Capital Raise to Fund Growth and Path to Possible Initial Public Offering
Quantum BioPharma Ltd. announced that its licensee, Unbuzzd Wellness Inc., is undertaking a $5 million capital raise through a Regulation D offering to fuel its growth and prepare for a possible IPO. Unbuzzd Wellness, known for its innovative beverage designed to accelerate alcohol metabolism, will utilize this capital for marketing and expansion efforts. The company has demonstrated significant clinical trial findings, showcasing the effectiveness of its product in reducing hangover symptoms and enhancing cognitive clarity. This strategic move aligns with Quantum BioPharma's broader innovative asset development in the biopharmaceutical sector.
Read more →QNTM▲ +20%on this news· ran to +41% by day 1
Quantum BioPharma Announces First Person with Multiple Sclerosis (MS) Scanned in Joint Study with Massachusetts General Hospital
Quantum BioPharma Ltd. announced the successful scanning of the first patient with multiple sclerosis (MS) in collaboration with Massachusetts General Hospital. This joint study aims to validate a novel PET imaging technique designed to monitor myelin integrity and demyelination in MS patients. The imaging method utilizes the PET tracer [18F]3F4AP, which has shown promise as a biomarker for assessing changes in demyelination. The advancements in imaging technology are expected to enhance treatment efficacy assessments for MS therapies, particularly those aimed at protecting and repairing the myelin sheath.
Read more →QNTMQuantum BioPharma Announces Intention to Declare Special Dividend of Contingent Value Rights (CVRs) Linked to Future Litigation Settlement Proceeds
Quantum BioPharma Ltd. has announced its plan to declare a special dividend in the form of Contingent Value Rights (CVRs) for its Class B Subordinate Voting Shares. The CVRs will allow holders to receive a proportionate share of net proceedings from ongoing litigation against financial institutions, targeting over USD 700 million. Although the initiative is aimed at aligning shareholder interests, the company cautions that the dividends depend on the outcome of the legal proceedings, which remain uncertain.
Read more →QNTMQuantum Biopharma Purchases More Bitcoin (BTC) Bringing the Total Investment in Digital Assets to USD $5,000,000
Quantum BioPharma Ltd. has announced the purchase of additional Bitcoin and other cryptocurrencies, bringing its total investment in digital assets to USD $5,000,000. This strategic move reflects the company's confidence in the potential returns from these cryptocurrencies and aims to diversify its financing options. Furthermore, the company assures that all transactions are compliant with financial regulations. Quantum BioPharma plans to continue monitoring the cryptocurrency market and adjust its holdings as necessary.
Read more →QNTMQuantum BioPharma Clarifies It Has Not Changed Its Name
Quantum BioPharma Ltd. has issued a statement clarifying that it has not changed its name, addressing rumors regarding its identity on stock trading platforms. Misinformation also suggested an impending reverse takeover involving Unbuzzd Wellness Inc., which Quantum denies. The company remains the largest shareholder of Unbuzzd and maintains a royalty agreement on revenue. Quantum is focused on continuing its biopharmaceutical innovations, particularly in the treatment of neurodegenerative and metabolic disorders.
Read more →QNTM▲ +7%on this news· ran to +21% by day 1shared move
Quantum BioPharma Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza Bokhari
Quantum BioPharma Ltd. has announced a global legal settlement with Dr. Raza Bokhari, the company's former Executive Chairman, resulting in a payment of $2.35 million USD. The settlement resolves all disputes stemming from a proxy contest that began in January 2021 and prevents future litigation in Canada and the United States. The agreement enhances the company's financial stability without causing dilution for current shareholders, allowing them to refocus on their business operations and ongoing projects.
Read more →QNTM▲ +7.2%on this news· ran to +32% by day 3shared move
Quantum Biopharma Licensee Celly Nutrition Retains Leading Audit Firm MNP LLP to Advance Capital Raise and Go-Public Readiness and Changes Name To Unbuzzd Wellness Inc.
Quantum BioPharma Ltd. has licensed Unbuzzd Wellness Inc. and retained MNP LLP to conduct PCAOB audits in preparation for an IPO. Unbuzzd Wellness, formerly Celly Nutrition, boasts a scientifically-backed beverage aimed at accelerating alcohol metabolism and reducing hangover symptoms. This strategic move follows the recruitment of a New York investment bank for advising on capital raising efforts. The company also changed its name to Unbuzzd Wellness Inc., effective May 23, 2025, with no necessary actions required from shareholders regarding the name change.
Read more →QNTMQuantum BioPharma Receives Ethics Committee Approval for Phase 2 Clinical Trial of FSD202 for Nociplastic Pain in Patients with Idiopathic Mast Cell Activation Syndrome
Quantum BioPharma Ltd. has announced that its subsidiary, FSD Pharma Australia Pty Ltd., received approval from the Human Ethics Review Committee in Australia for a Phase 2 clinical trial of FSD202. This trial will assess the safety and efficacy of FSD202 in patients suffering from chronic widespread musculoskeletal nociplastic pain associated with idiopathic Mast Cell Activation Syndrome. The study plans to enroll 60 patients and aims to deliver results on pain intensity reduction by Day 28. The approval marks a significant step forward for the company in developing therapeutic options for inflammatory diseases.
Read more →QNTM▲ +8%on this news
Quantum BioPharma Partners with BitGo to Securely Store its Crypto Currency Assets
Quantum BioPharma Ltd. announced a partnership with BitGo Trust Company to securely manage and store its cryptocurrency assets, including Bitcoin and others. The collaboration aims to bolster Quantum's security and compliance as it engages more in digital asset management. CEO Zeeshan Saeed emphasized the importance of reliable custodianship for public companies in the evolving digital finance landscape. BitGo's reputation for secure custody solutions is expected to benefit Quantum significantly.
Read more →QNTM▼ -7.1%on this newsshared move
Quantum Biopharma Announces Signing of an Agreement with a Global Pharmaceutical Contract Research Organization to Prepare an IND (Investigational New Drug) Application Package for Lucid-21-302 (Lucid-MS), A First-In-Class Treatment for Multiple Sclerosis
Quantum BioPharma has announced a significant agreement with a global pharmaceutical contract research organization to prepare the IND application package for its innovative treatment, Lucid-21-302, aimed at multiple sclerosis. This first-in-class compound, which has demonstrated the ability to prevent demyelination in preclinical models, is a patented new chemical entity. The company anticipates submitting the IND application to the FDA in the fourth quarter of 2025, marking a pivotal step towards initiating a Phase 2 trial. Additionally, the announcement underlines Quantum's focus on advancing solutions for neurodegenerative disorders.
Read more →QNTM▲ +19.6%on this newsshared move
Quantum Biopharma Purchases an Additional USD $1 Million of Bitcoin and Other Cryptocurrencies to Hold BTC Treasury and To Generate Staking Revenue. Bringing the Total Investment in Digital Assets to USD $4,500,000
Quantum BioPharma Ltd. (NASDAQ: QNTM) has announced a new investment of USD $1 million in Bitcoin and other cryptocurrencies, bringing its total digital asset investment to USD $4.5 million. The company believes that cryptocurrencies can serve as a hedge against currency fluctuations and yield returns for shareholders. Quantum aims to facilitate future transactions in cryptocurrencies, ensuring compliance with all relevant regulations. This strategic move is part of the company’s broader financial strategy.
Read more →QNTM▲ +12%on this news· ran to +34% by day 3shared move
Quantum BioPharma to Attend Sidoti Micro-Cap Investor Conference and the AGP Virtual Healthcare Conference
Quantum BioPharma Ltd. has announced its participation in the Sidoti Micro-Cap Conference and the A.G.P. Virtual Healthcare Conference in May 2025. The Head of Finance and M&A, Jason Sawyer, will host meetings with institutional investors and deliver a presentation at the Sidoti conference. This engagement aims to boost investor relations and highlight the company's innovative biopharmaceutical solutions. Quantum BioPharma focuses on developing treatments for neurodegenerative and metabolic disorders.
Read more →QNTMQuantum BioPharma Announces Completion of Dosing in 90-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-MS for Multiple Sclerosis
Quantum BioPharma has completed dosing in 90-day oral toxicity and toxicokinetic studies for its drug Lucid-21-302, aimed at treating Multiple Sclerosis. This completion marks a key milestone in the development program, which is intended to support an IND application with the US FDA. The company expresses optimism about Lucid-21-302's potential as a first-in-class treatment and plans to begin Phase 2 trials soon.
Read more →QNTM▲ +10.8%on this news
Quantum Biopharma Files Amended Complaint Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing
Quantum BioPharma Ltd. has filed an amended complaint against CIBC World Markets and RBC Dominion Securities, alleging market manipulation through spoofing techniques that have depressed its stock price. The lawsuit claims damages exceeding $700 million USD and follows a previous complaint filed in October 2024, which was met with a motion to dismiss. The company plans to strengthen its claims with additional evidence and remains open to discussions with the involved banks. Legal representation is provided on a contingency basis, minimizing financial strain on Quantum BioPharma.
Read more →QNTMQuantum BioPharma to Host Business Update Conference Call on Tuesday, May 6, 2025 at 4:30 p.m. Eastern Time
Quantum BioPharma Ltd. has announced that it will host a Business Update Conference Call on May 6, 2025, at 4:30 p.m. Eastern Time. The call will cover recent year-end financial results, regulatory initiatives, and commercial-readiness activities. Attendees will be able to view a presentation during the call and access further materials through the company's investor relations section. CEO Zeeshan Saeed and Head of Finance Jason Sawyer will lead the discussion, followed by a Q&A session.
Read more →QNTMQuantum Biopharma Announces Advocate Against Naked Short Selling and Stock Manipulation, Kevin Malone Appointed as Board Advisor
Quantum BioPharma Ltd. has appointed Kevin Malone as a board advisor, aiming to combat naked short selling and stock manipulation. Malone, a seasoned financial advisor, brings expertise in recognizing patterns in manipulated markets and is dedicated to enhancing financial literacy. CEO Zeeshan Saeed expressed confidence that Malone's experience will significantly benefit the company's mission, especially in their development of treatments for multiple sclerosis. As part of its ongoing efforts, Quantum BioPharma is also advancing its clinical programs in innovative therapeutics.
Read more →QNTMFiled by newsfilecorp.com Quantum BioPharma Corporate Update Toronto, Ontario
Quantum BioPharma Ltd. has released a corporate update detailing several actions taken to enhance its strategic position. The company has granted 60,000 restricted share units to incentivize its workforce and has approved the settlement of existing debts through the issuance of Class B Shares. The firm continues its focus on developing innovative treatments for neurodegenerative and metabolic disorders, with its lead compound aimed at addressing multiple sclerosis. Additionally, the company retains a stake in Celly Nutrition, which is part of its broader growth strategy in biotech solutions.
Read more →QNTMQuantum Biopharma Wins Reconsideration Motion by Dr. Raza Bokhari at the Court of Appeal for Ontario
Quantum BioPharma Ltd. announced that the Ontario Court of Appeal dismissed a reconsideration motion by Dr. Raza Bokhari, affirming the previous arbitration award in favor of the company. Dr. Bokhari, who was CEO of FSD Pharma Inc. before its rebranding to Quantum BioPharma, was ordered to pay a total of $180,000 in costs due to the dismissal of his claims. The company is now moving forward to officially collect the awarded amounts as part of its legal and operational proceedings.
Read more →QNTM▼ -6.8%on this newsshared move
Quantum BioPharma Licensee Celly Nutrition Announces Landmark Partnership with the Asian American Trade Associations Council (AATAC) to Expand Retail Availability of its Alcohol Detox Beverage unbuzzd™
Quantum BioPharma's licensee, Celly Nutrition, has formed a significant partnership with the Asian American Trade Associations Council (AATAC) to enhance the retail availability of its alcohol detox beverage unbuzzd™. This partnership will focus on promoting unbuzzd™ in convenient stick pack formats, aiming to increase sales and customer access. AATAC's extensive network, which includes more than 80,000 retail locations across the U.S. and Puerto Rico, is expected to facilitate this expanded distribution and capitalize on rising consumer interest in health and wellness products.
Read more →QNTMQuantum BioPharma Licensee Celly Nutrition Launches unbuzzd in Puerto Rico
Quantum BioPharma's licensee, Celly Nutrition, has announced the launch of their product unbuzzd, an alcohol detoxification beverage, in Puerto Rico. This product, which aids in alcohol metabolism and reducing hangover symptoms, will be distributed by FUSION Distribution Group. The launch marks a significant step for Celly Nutrition as they aim to expand their market presence across the Caribbean. Unbuzzd is backed by scientific research and will be available in various retail and service outlets in Puerto Rico.
Read more →QNTMQuantum BioPharma Announces Joint Clinical Study With Massachusetts General Hospital Scientists to Validate a Novel Positron Emission Tomography (PET) Imaging Technique to Monitor Demyelination In Multiple Sclerosis
Quantum BioPharma Ltd. has announced a joint clinical study with Massachusetts General Hospital to validate a novel PET imaging technique for monitoring demyelination in multiple sclerosis (MS) patients. The study aims to assess the sensitivity of the imaging technique, [18F]3F4AP, in detecting changes in myelin integrity. The principal investigator, Dr. Pedro Brugarolas, along with Dr. Eric Klawiter, will conduct the study to evaluate the potential of this PET biomarker in tracking responses to MS therapies. Quantum BioPharma's Lucid-MS program aims to prevent demyelination, making this study a significant step in MS research.
Read more →QNTM▼ -9.9%on this newsshared move
Quantum Biopharma Announces Closing of Final $2.42 Million Tranche of $5 Million Total Financing on Improved Terms
Quantum BioPharma Ltd. has successfully closed the final tranche of its financing, raising a total of $5 million to support its ongoing drug development efforts. This financing will facilitate the advancement of innovative treatment options, particularly the formulation of rekvry™, an alcohol misuse treatment. The company believes that rekvry™ addresses a crucial need in healthcare, potentially easing the burden on resources in emergency and hospital settings. With sufficient cash flow, Quantum anticipates being able to execute its development plans at least until the first quarter of 2027.
Read more →QNTMQuantum Biopharma’s 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern
Quantum BioPharma Ltd. (NASDAQ: QNTM) has reported strong financial performance for 2024, removing its material uncertainty related to going concern, and maintaining $12.1 million in cash. The company saw significant improvements in operating efficiency, reducing operating expenses by over 32% and achieving an 18% reduction in net loss compared to the previous year. Positive developments include successful clinical trial results for its product unbuzzd aimed at alcohol detoxification and progress in its multiple sclerosis drug, Lucid-MS. The company is also exploring an IPO for its licensee, Celly Nutrition, to further capitalize on its market opportunities.
Read more →QNTM▲ +20.6%on this newsshared move
Quantum Biopharma Announces Leading Crusader Against Naked Short Selling and Stock Manipulation, Terry Lynch Elected to Board of Directors
Quantum BioPharma Ltd. has appointed Terry Lynch to its board of directors, filling the vacancy left by Dr. Sanjiv Chopra's resignation. Lynch, known for combating stock manipulation, is expected to bring his vast experience in micro-cap markets to benefit the company. The company also announced a grant of stock options to Lynch with a set exercise price. This move is perceived as a strategic effort to enhance corporate governance and address market challenges.
Read more →QNTM▲ +18.6%on this news· ran to +43% by day 1shared move
Quantum BioPharma Licensee Celly Nutrition Expands unbuzzd™ Alcohol Detox Product Lineup for Retail Sales
Quantum BioPharma's licensee, Celly Nutrition, has launched an expansion of its unbuzzd™ alcohol detox product line with new ultra-portable single-use powder sticks. These are available in an 8-pack display box specifically designed for convenience stores, aiming to enhance retail availability across the US. The product has shown effectiveness in clinical trials, which could support substantial market growth. Quantum BioPharma retains a significant stake in Celly Nutrition and will benefit from ongoing royalty payments from sales.
Read more →QNTMQuantum BioPharma Continues to Grow Its Crypto Assets and Diversify Its Treasury With the Purchase of Another USD $1,500,000 Worth of Bitcoin (BTC) and Other Cryptocurrencies
Quantum BioPharma Ltd. has announced the purchase of an additional USD $1,500,000 worth of Bitcoin and other cryptocurrencies, increasing its total investment to USD $3,500,000. This strategic move comes with the company's intention to leverage cryptocurrencies for future financing and transactions. The company emphasizes compliance with financial regulations while holding its assets in a secure environment. This decision reflects the company's belief in the potential of digital currencies to offer returns and act as a hedge against traditional currency fluctuations.
Read more →QNTMQuantum Biopharma Announces Completion of the Phase 1 Multiple Ascending Dose Clinical Trial for its Experimental Multiple Sclerosis Drug Lucid-21-302
Quantum BioPharma has successfully completed a Phase 1 clinical trial for its drug Lucid-21-302 aimed at treating multiple sclerosis. The trial, which was conducted on healthy adult participants, concluded with no safety concerns identified by the Safety Review Committee. Lucid-21-302 is a first-in-class neuroprotective compound designed to stabilize the myelin sheath. Following this milestone, the company is gearing up for the next steps in clinical development, including the planning of a Phase 2 trial with MS patients.
Read more →QNTM▼ -5.2%on this news· ran to -31% by day 3
Quantum BioPharma Continues to Diversify its Treasury with the Purchase of Another USD $1,000,000 Worth of Bitcoin (BTC) and Other Cryptocurrencies
Quantum BioPharma Ltd. has made an additional investment of USD $1,000,000 in Bitcoin and other cryptocurrencies, bringing its total cryptocurrency investment to USD $2,000,000. This strategic move reflects the company's belief in the potential of cryptocurrencies to provide returns for shareholders and serve as a hedge against currency fluctuations. The company plans to continue engaging with cryptocurrencies for financing and transactions, while ensuring compliance with relevant regulations. Quantum BioPharma emphasizes that all its cryptocurrency holdings are managed through a compliant custodian.
Read more →QNTMQuantum Biopharma Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program
Quantum BioPharma Ltd. has announced its collaboration with MZHCI, LLC, part of the MZ Group, to spearhead a strategic investor relations and financial communications program. This initiative aims to heighten the company's presence in the investment community by showcasing its innovative pipeline focused on brain disorders and alcohol health. The engagement with MZ is structured for an initial duration of two months and aims to facilitate better interactions with institutional and retail investors, reflecting Quantum's commitment to addressing significant healthcare challenges.
Read more →QNTM▲ +8.2%on this newsshared move
Quantum Biopharma Engages Enterprise Canada and Empire Market Ventures to Lead Public Communications and Investor Awareness Programs
Quantum BioPharma Ltd. has engaged Enterprise Canada and Empire Market Ventures to enhance its public relations and investor awareness efforts. These agencies will assist the company in developing key messages and improving its visibility in the investment community. This strategic decision follows a thorough review of the company’s capital resources. Quantum BioPharma continues to focus on the commercialization of its innovative products, including unbuzzd™ and LUCID-21-302, which have promising market potential.
Read more →QNTM▲ +69%on this newsshared move
Quantum Biopharma Licensee Celly Nutrition Retains Leading New York Investment Bank to Advise on Capital Raise and Possible Initial Public Offering Following Highly Positive Results from unbuzzd™ Clinical Study
Quantum BioPharma's licensee, Celly Nutrition, is taking steps to raise up to $10 million to support the growth of its product 'unbuzzd', which has demonstrated positive results in clinical trials. Celly Nutrition has engaged a prominent New York investment bank to assist in this capital raise and to explore options for an initial public offering on a U.S. exchange. The clinical study showed that 'unbuzzd' significantly reduces blood alcohol concentration and improves cognitive function after alcohol consumption, suggesting strong market demand for the product.
Read more →QNTM▲ +111%on this news· ran to +256% by day 3shared move
Quantum Biopharma Announces the Success of unbuzzd™ Clinical Trial
Quantum BioPharma announced the successful completion of its clinical trial for unbuzzd™, a dietary supplement aimed at reducing alcohol intoxication. Results demonstrated that unbuzzd™ significantly accelerated the reduction of blood alcohol concentration and improved participants' alertness. The product was well-tolerated with no adverse side effects reported, and it effectively alleviated hangover symptoms. The findings underscore the potential of unbuzzd™ to enhance responsible alcohol consumption.
Read more →QNTMQUANTUM BIOPHARMA IN COURT WITH DR. RAZA BOKHARI ON JANUARY 24, 2025 SEEKING A COURT ORDER TO DECLARE HIM TO BE A VEXATIOUS LITIGANT AND OTHER LITIGATION UPDATES Awards in favour of Quantum BioPharma Total Approximately
Quantum BioPharma is scheduled to appear in the Ontario Superior Court of Justice on January 24, 2025, to seek a declaration of Dr. Raza Bokhari as a vexatious litigant. This follows a series of arbitration outcomes in favor of Quantum BioPharma, amounting to approximately $3 million. Quantum is also working to confirm arbitration awards in the U.S. District Court to collect these funds. Bokhari, who previously served as CEO, is appealing a judgment related to these financial matters.
Read more →QNTMQuantum Biopharma Ltd. Now Trading on Upstream Under QNTM TORONTO, ON / ACCESSWIRE /
Quantum BioPharma Ltd. has announced its dual listing on the Upstream trading platform under the ticker symbol QNTM. This move allows international investors to access Quantum shares conveniently via a mobile app, enhancing trading opportunities. CEO Zeeshan Saeed expressed excitement about the expansion, aiming to provide new value and liquidity for shareholders while continuing to trade on other exchanges. The Upstream market operates round the clock, offering real-time trading and settlement processes.
Read more →QNTMFORM 7 MONTHLY PROGRESS REPORT Name of Listed Issuer: Quantum BioPharma Ltd. (the "Issuer", or "Quantum") Trading Symbol: QNTM Number of Outstanding Listed Securities: 2,299,748 Date
Quantum BioPharma Ltd. released its Monthly Progress Report detailing several key developments for December 2024. The company successfully closed the first and second tranches of a private placement offering, raising $1 million. Additionally, the safety review committee has recommended advancing to the next phase of its clinical trial for Lucid-21-302. Furthermore, Quantum made a strategic purchase of $1 million in Bitcoin and other cryptocurrencies, showcasing its commitment to innovative financial practices.
Read more →QNTMQUANTUM BIOPHARMA LTD. APPROVED TO DUAL LIST ON UPSTREAM Trading to become available January 14th under QNTM' Toronto, Ontario
Quantum BioPharma Ltd. has received approval to dual list its shares on Upstream, a global trading platform, effective January 14, 2025. This move allows the company to reach international investors and enhance liquidity and price discovery for its shares. The dual listing is aimed at empowering non-U.S. investors to trade easily through Upstream's app, which supports contemporary payment methods. Quantum BioPharma's CEO underscored the listing's potential to build shareholder value while developing innovative therapies for neurodegenerative and metabolic disorders.
Read more →QNTM▼ -13.3%on this news
QUANTUM BIOPHARMA DIVERSIFIES TREASURY WITH THE PURCHASE OF USD $1,000,000 OF BITCOIN (BTC) AND OTHER CRYPTOCURRENCIES AND TO ALLOW FOR FUTURE FINANCINGS AND OTHER TRANSACTIONS IN CRYPTOCURRENCY Toronto, Ontario
Quantum BioPharma Ltd. has announced the purchase of $1,000,000 worth of Bitcoin and other cryptocurrencies as part of its treasury diversification strategy. The company aims to utilize these cryptocurrency holdings for future financings and transactions, reflecting their belief in the potential of cryptocurrencies. The move, supported by the Board of Directors, emphasizes full compliance with financial regulations ensuring secure and legal processes. This initiative is seen as a step towards aligning with emerging financial trends and market legitimacy for Bitcoin.
Read more →QNTMQuantum BioPharma Previously Known as FSD Pharma (Nasdaq:HUGE) (CSE:HUGE) Invites Shareholders to Come Forward and Join Hands With the Company in the US700M$+ Court Case the Company Has Filed Against CIBC, RBC, and Other
Quantum BioPharma, formerly FSD Pharma, has filed a lawsuit against several financial institutions, alleging market manipulation that led to substantial financial and emotional losses for the company and its shareholders. The company is inviting affected shareholders to come forward and participate in the case, emphasizing that the stronger the group, the better the chances of a successful claim. Legal teams are engaged on a contingency basis, ensuring no upfront legal fees for the company during this process. The lawsuit seeks damages exceeding $700 million.
Read more →QNTMQUANTUM BIOPHARMA ANNOUNCES THAT SENTINEL DOSING HAS STARTED THE PHASE-1 MULTIPLE ASCENDING DOSE CLINICAL TRIAL FOR LUCID-21-302 (LUCID-MS) IN AUSTRALIA Toronto, ON
Quantum BioPharma has announced the start of sentinel dosing for its Phase-1 trial of Lucid-21-302, aimed at treating multiple sclerosis. This milestone suggests progress towards future human phase-2 efficacy trials, with executives expressing optimism about the therapy's potential. The trial is being conducted in Australia, and the company has engaged various firms for investor relations to enhance market awareness. Quantum BioPharma's commitment to developing innovative solutions for neurodegenerative disorders underpins this advancement.
Read more →QNTM▼ -17.3%on this news
QUANTUM BIOPHARMA (NASDAQ: QNTM) POSTS LINK ON ITS WEBSITE TO ACCESS THE FILED COMPLAINT AGAINST CIBC WORLD MARKETS, RBC DOMINION SECURITIES AND OTHERS, SEEKING DAMAGES IN EXCESS OF $700,000,000 USD, FOR POSSIBLE STOCK P
Quantum BioPharma filed a complaint against CIBC World Markets, RBC Dominion Securities, and others in the U.S. District Court, alleging market manipulation that resulted in significant financial damages exceeding $700 million. The complaint highlights the use of 'spoofing' techniques that allegedly harmed the company's stock price between January 2020 and August 2024. In response to inquiries, the company has made the complaint accessible on its website. The lawsuit poses risks to the stability of Quantum BioPharma and could lead to a prolonged legal process affecting its operations and market position.
Read more →QNTM▼ -9.8%on this news· ran to -25% by day 1shared move
QUANTUM BIOPHARMA (NASDAQ: QNTM) FILES A US FEDERAL LAWSUIT AGAINST CIBC WORLD MARKETS, RBC DOMINION SECURITIES AND OTHERS, SEEKING DAMAGES IN EXCESS OF $700,000,000 USD, FOR POSSIBLE STOCK PRICE MANIPULATION/SPOOFING Ch
Quantum BioPharma has filed a federal lawsuit against CIBC World Markets, RBC Dominion Securities, and others for alleged stock price manipulation and spoofing. The company claims to have uncovered evidence indicating that these entities engaged in practices that artificially depressed its share price from over $460 in January 2020 to approximately $7.55 in October 2024. They seek damages exceeding $700 million, believing that these actions severely harmed both the firm and its shareholders. The complaint outlines significant investigations supporting their claims of market manipulation over several years.
Read more →QNTM▼ -8.3%on this news
Quantum BioPharma Ltd. Provides Update from Celly Nutrition Signing a Master Distribution Agreement with FUSION Distribution Group across Puerto Rico, The Caribbean, and parts of Central and South America Toronto, ON
Quantum BioPharma Ltd. announced a Master Distribution Agreement between its subsidiary Celly Nutrition Corp. and FUSION Distribution Group, aimed at expanding the distribution of the innovative beverage product unbuzzd across Puerto Rico, The Caribbean, and parts of Central and South America. This agreement is expected to leverage FUSION's established network to introduce unbuzzd, a product designed to support alcohol metabolism and promote alertness. The partnership is viewed as pivotal by company executives for expanding their market presence. However, there are underlying risks regarding the successful launch and validation of product efficacy in clinical trials.
Read more →QNTMQUANTUM BIOPHARMA PROVIDES CORPORATE UPDATE Toronto, ON
Quantum BioPharma Ltd. has announced a corporate update that includes the grant of stock options to directors, officers, employees, and consultants. The company is also retaining services from three media firms to increase its market presence and shareholder communication. Additionally, it is focused on the development of its lead compound, Lucid-MS, intended to treat multiple sclerosis. The updates reflect the company's strategic moves to enhance its investment activities and market visibility.
Read more →QNTMQuantum BioPharma Closes Private Placement Offering Toronto
Quantum BioPharma has successfully closed a non-brokered private placement offering, raising a total of $36.00 through the issuance of Class A multiple voting shares at a price of $6.00 each. The offering was approved by shareholders during the annual meeting on July 22, 2024, and the proceeds will be used for general working capital purposes. Notably, the Class A shares were purchased entirely by insider entities, including the CEO and a director, which qualifies as a related-party transaction under Canadian regulations.
Read more →QNTMQuantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis. TORONTO, ON / ACCESSWIRE /
Quantum Biopharma has signed an agreement with Ingenu CRO to conduct a clinical study focusing on disease progression in patients with primary progressive multiple sclerosis. This collaboration is aimed at facilitating a future phase 2 clinical trial involving Lucid-21-302. The study marks a significant step forward in Quantum Biopharma's research efforts in the field of multiple sclerosis. Dr. Andrzej Chruscinski expressed optimism about the importance of this study for their research program.
Read more →QNTMQUANTUM BIOPHARMA RECEIVES NASDAQ NOTIFICATION OF REGAINING COMPLIANCE WITH NASDAQ'S MINIMUM BID PRICE REQUIREMENT AND COMPLETES DEBT SETTLEMENTS Toronto, Ontario
Quantum BioPharma Ltd. has announced that it has regained compliance with Nasdaq's minimum bid price requirement, allowing the company to remain listed on the exchange. The company also completed debt settlements totaling $450,000 with its executives through the issuance of Class B Shares, which will help preserve cash. Additionally, a plan for a private placement of Class A Shares has been approved by shareholders, potentially restoring significant voting rights for these shares.
Read more →QNTM▼ -8.3%on this news· ran to -27% by day 1
Quantum Biopharma announces Celly Nutrition Launches unbuzzd grab-and-go stick packs on Amazon.com so you can "own NOW and what's NEXT". Toronto, ON
Quantum Biopharma has announced the launch of unbuzzd, a new product designed to aid individuals in recovering from the effects of alcohol consumption. This innovative solution, consisting of Clear Eyed Citrus Powder Sticks, is now available on Amazon.com. The product is developed by a team with extensive experience in the beverage industry, aiming to reshape perceptions of alcohol recovery. Backed by significant expertise, unbuzzd promotes faster recovery and improved hydration for consumers seeking to manage their drinking aftermath effectively.
Read more →QNTMQUANTUM BIOPHARMA ANNOUNCES INTENTION TO COMPLETE DEBT SETTLEMENTS AND PROVIDES CORPORATE UPDATE Toronto, Ontario
Quantum BioPharma has announced several corporate updates, including management changes and plans for debt settlements. Donal Carroll will take on the role of Chief Financial Officer, along with other key appointments. The company will also cancel existing options and grant new restricted share units, with settlements intended to preserve cash. However, these debt settlements involve related party transactions, which may require minority shareholder approval.
Read more →QNTM▼ -6.1%on this news
Quantum Biopharma Ltd. Condensed consolidated interim financial statements For the three and six months ended
Quantum Biopharma Ltd. released its condensed consolidated interim financial statements for the periods ending June 30, 2024, and 2023. The company reported a substantial net loss of $5.44 million for the first half of 2024, with operating expenses rising sharply. The accumulated deficit has increased, reaching $162.92 million, which raises concerns about the company's financial stability.
Read more →QNTMFSD Pharma Completes Name Change to Quantum BioPharma and 65:1 Consolidation - Trading Under New Ticker Symbol "QNTM" Toronto
FSD Pharma has officially changed its name to Quantum BioPharma and completed a 65:1 share consolidation, effective August 15, 2024. Trading under the new ticker symbol "QNTM," the company aims to enhance its portfolio of innovative biopharmaceutical assets. A private placement has also been closed, raising $72 for general working capital. This strategic shift is expected to improve market perception and stock dynamics for Quantum BioPharma.
Read more →QNTMFSD Pharma Inc. Condensed consolidated interim financial statements For the three and six months ended
FSD Pharma Inc. released its condensed consolidated interim financial statements for the three and six months ending June 30, 2024. The report indicates a net loss from operations of approximately $5.44 million, which is an increase from $15.45 million compared to the previous year. Additionally, the company's total assets decreased to $15.25 million from $17.47 million, while its accumulated deficit also rose, presenting ongoing financial difficulties for the firm.
Read more →QNTMFSD Pharma Announces Share Consolidation and Name Change Toronto
FSD Pharma has announced a proposed share consolidation and a name change to Quantum BioPharma Ltd. The consolidation aims to comply with Nasdaq's minimum bid price requirement, reducing the number of Class A and Class B shares significantly. Additionally, the company plans to offer new shares in a private placement to existing shareholders, potentially increasing their voting power. The new trading symbol, 'QNTM', will take effect on August 15, 2024, on both the CSE and Nasdaq.
Read more →QNTMFSD Pharma Provides Update on its Investment in Celly Nutrition Corp. Who Secures Additional Financing to Launch unbuzzd Stick Packs this Month - Created by a World-Class Pharmaceutical Research & Development Team Toront
FSD Pharma has announced an update regarding its investment in Celly Nutrition Corp., which is set to launch an innovative beverage product named unbuzzd. This product is designed to expedite alcohol metabolism and improve recovery from alcohol consumption. The company has secured additional financing of approximately $203,469 as part of its first round of fundraising to support the product's launch later this month. Celly Nutrition plans to provide unbuzzd in convenient stick packs, making it an accessible solution for consumers looking to responsibly manage alcohol effects.
Read more →QNTMFSD PHARMA INC. NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF THE SHAREHOLDERS TO BE HELD ON JULY 22, 2024 AND MANAGEMENT INFORMATION CIRCULAR DATED: JUNE 10, 2024 FSD PHARMA INC. 199 Bay St., Suite 4000 Toronto, Ontar
FSD Pharma Inc. has announced the date for its Annual General and Special Meeting of Shareholders, scheduled for July 22, 2024, in Toronto. The meeting will involve discussions on the company's financial statements, election of directors, and other key corporate resolutions. Notably, shareholders will also consider a proposal for share consolidation and a potential company name change. Shareholders are encouraged to review the accompanying management information circular for detailed voting instructions and proposals.
Read more →QNTMFORM 51-102F3 AMENDED AND RESTATED MATERIAL CHANGE REPORT Note to Reader: This Amended and Restated Material Change Report is being filed to amend the disclosure in Section 5.1 of the Material Change Report of FSD Pharma
FSD Pharma Inc. filed an Amended and Restated Material Change Report to provide additional disclosure regarding its recent private placement offering, completed on December 4, 2023. The offering resulted in the issuance of 24 class A multiple voting shares at a price of $1.90 each, totaling $45.60 in gross proceeds. The report highlights the intended use of proceeds for general working capital and reaffirms the company's governance process for the transaction. Insiders participated in the offering, signaling confidence in the company's future prospects.
Read more →QNTMFSD Pharma provides Corporate Update Toronto
FSD Pharma has announced a corporate update detailing its engagement with Totaligent to boost market awareness and communication with investors. The company has also issued shares to settle outstanding debts and continues developing its lead drug, Lucid-MS, aimed at treating neurodegenerative conditions. While the firm is optimistic about its initiatives, it cautions that drug development is at an early stage and may face several uncertainties and risks. Overall, this update reflects FSD Pharma's strategic initiatives and ongoing research efforts.
Read more →QNTMFSD Pharma, Inc. wins Final Judgment to Confirm Arbitration Award of $3,059,998 plus interest entered against Dr. Raza Bokhari, currently serving as Chairman and CEO of Medicus Pharma Ltd. Toronto, ON
FSD Pharma, Inc. has received a Final Judgment confirming an arbitration award against Dr. Raza Bokhari, the current Chairman and CEO of Medicus Pharma Ltd. This judgment, granted by the United States District Court for the Eastern District of Pennsylvania, includes monetary damages totaling $3,059,998 plus interest. The arbitration followed after FSD terminated Bokhari in July 2021, which he legally challenged but ultimately lost. FSD plans to use all available means to collect the awarded amount from Bokhari, enhancing its legal and financial standing.
Read more →QNTMFSD Pharma Receives Ethics Committee Approval for a Phase-1 Multiple Ascending Doses Clinical Trial for Lucid-21-302 (Lucid-MS) in Australia. Toronto, ON
FSD Pharma has received ethics committee approval to initiate a Phase-1 clinical trial for its leading drug candidate, Lucid-21-302, aimed at treating multiple sclerosis. This trial will assess the safety and pharmacokinetics of this novel neuroprotective compound in healthy adult participants. Lucid-21-302 is positioned as a groundbreaking therapy that potentially prevents demyelination, addressing fundamental issues associated with multiple sclerosis. The approval is a critical step in advancing FSD Pharma's commitment to treating neurodegenerative diseases.
Read more →QNTMFSD Pharma enters into an exclusive option agreement with the University of Southern California to evaluate novel dietary supplement technology for unbuzzd and other business applications. Toronto, ON
FSD Pharma has signed an exclusive option agreement with the University of Southern California to evaluate novel dietary supplement technology, specifically for its product unbuzzd. This technology aims to enhance the effectiveness of existing ingredients and supports FSD's broader strategy of innovation in health solutions. The agreement allows FSD a six-month period for evaluation, with options for renewal or licensing thereafter. Notably, the partnership involves experienced leaders from the beverage industry, underscoring FSD's commitment to leveraging collaborative expertise in developing health products.
Read more →QNTMFSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd in Acute Alcohol Intoxication Toronto, ON
FSD Pharma has announced that its METAL-2 trial has received Institutional Review Board (IRB) approval, permitting the company to begin recruiting participants for a study focused on the safety and efficacy of its product, unbuzzd, in treating acute alcohol intoxication. This marks a significant advancement for the company in its research initiatives. FSD Pharma retains a substantial interest in Celly Nutrition, the company that holds the OTC version of unbuzzd. Despite the positive developments, the company experiences inherent risks as the drug development process is still at an early stage.
Read more →QNTMFSD Pharma, Inc. wins Petition to Confirm Arbitration Awards entered against Dr. Raza Bokhari Totaling Over $3 million CAD, plus interest. Toronto, ON
FSD Pharma, Inc. has won a petition to confirm arbitration awards totaling over CAD 3 million against former CEO Dr. Raza Bokhari. The United States District Court affirmed these awards following a comprehensive arbitration process that ruled in FSD's favor. This development could lead to final judgment and further financial reinforcement for FSD. The company continues to advance its biotech initiatives alongside this legal victory.
Read more →QNTMFSD Pharma Submits a Clinical Trial Protocol to Study the Safety and Efficacy of Unbuzzd in Acute Alcohol Intoxication Toronto, ON
FSD Pharma has submitted a clinical trial protocol for Unbuzzd, focused on evaluating its safety and efficacy in tackling acute alcohol intoxication. This protocol is now pending review by an institutional review board, with participant recruitment to commence upon approval. The METAL-2 trial will assess Unbuzzd's effectiveness in healthy volunteers, representing a crucial step for the company in addressing alcohol misuse disorders. The announcement also reflects the ongoing development of the company's other drug candidates, including Lucid-MS, for serious health challenges.
Read more →QNTMFSD Pharma Provides Corporate Update Toronto, ON
FSD Pharma Inc. has announced a new investor relations services agreement with IR Agency LLC, effective May 22, 2024. This agreement aims to improve the company's communication with the financial community through various promotional activities. FSD Pharma remains focused on developing innovative pharmaceuticals for neurodegenerative disorders and has made progress with its lead drug candidate, Lucid-MS. However, the company acknowledges the associated risks and uncertainties prevalent in early-stage drug development.
Read more →QNTMFSD Pharma Provides Update on Celly Nu's New Packaging for unbuzzd(TM) TORONTO, ON / ACCESSWIRE /
FSD Pharma has announced an update regarding the rebranding of its product unbuzzd, a beverage designed to aid in alcohol metabolism. Celly Nutrition Corp. has collaborated with branding agency Six+One to introduce new packaging and a logo that reflect a vibrant and upscale aesthetic. This rebranding is expected to enhance consumer engagement as the product prepares for its summer launch. The unique formulation of unbuzzd includes vitamins and botanical extracts aimed at restoring mental clarity and promoting responsible drinking.
Read more →QNTMFSD Pharma Inc. Condensed consolidated interim financial statements For the three months ended
FSD Pharma Inc. has reported its condensed consolidated interim financial statements for the three months ending March 31, 2024, showing a significant decline in cash reserves and an increased net loss from operations. Total operating expenses have soared, reaching over $2 million, while the company's accumulated deficit has also widened. Comparatively, the same period last year saw less severe losses and higher cash balances. These factors indicate ongoing financial difficulties for the biopharmaceutical company as it navigates increasing operational costs.
Read more →QNTMFSD Pharma Submits a Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia Toronto, ON
FSD Pharma has submitted a Phase-1 clinical trial application for Lucid-21-302, a novel neuroprotective compound aimed at treating multiple sclerosis. This application is currently under review by an ethics committee in Australia, marking a key progression in the drug's development. Previous trials demonstrated the safety and tolerability of Lucid-21-302, which is designed to prevent damage to the myelin sheath in nerve fibers. The company remains optimistic about advancing this compound into further clinical testing.
Read more →QNTMFSD Pharma Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy ofunbuzzd in an Induced State of Alcohol Intoxication To
FSD Pharma has signed an agreement with the Applied Science and Performance Institute (ASPI) to conduct a clinical trial evaluating the efficacy of its dietary supplement, unbuzzd, in inducing alcohol intoxication. This double-blind study will involve healthy volunteers and aims to compare unbuzzd's effects against a placebo. The trial underscores FSD Pharma's focus on addressing alcohol misuse disorders and positions it strategically within the health and wellness sector. Despite positive expectations for the study, the company acknowledges the inherent uncertainties associated with drug development and regulatory approval.
Read more →QNTMFSD Pharma Provides Update from Celly Nu's Partnership with Six+One for unbuzzd Toronto, ON
FSD Pharma has announced an update regarding its partnership with Celly Nutrition Corp. for the launch of unbuzzd, a beverage designed to aid alcohol metabolism and mental alertness. Celly Nu has formed a strategic alliance with Six+One, aiming to expand the product's market presence in the United States. The collaboration focuses on comprehensive brand development, including packaging and visual identity, led by experienced industry executives. This initiative reflects a growing trend in wellness products that resonate with consumer values and desires.
Read more →QNTMFSD Pharma Provides Another Update on Celly Nu's Anticipated Launch of unbuzzd Toronto, ON
FSD Pharma has provided an update on Celly Nutrition Corp.'s upcoming launch of unbuzzd, a beverage designed to aid in alcohol metabolism. The product's development is supported by a partnership with BevSource, which will assist in production and distribution. Celly Nu is led by experienced executives from successful beverage brands, facilitating a strong market entry. However, FSD Pharma cautions that any projections about the launch and product effectiveness involve inherent risks and uncertainties.
Read more →QNTMFSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products Toronto, ON
FSD Pharma Inc. has announced an expansion of its investigative pipeline to include potential products targeting weight loss and liver health. The company is examining various ingredients and dietary supplements that may improve liver health and assist in weight management. These initiatives include efforts aimed at enhancing alcohol metabolism and mitigating the effects of acute alcohol intoxication. The move signifies FSD Pharma's commitment to addressing metabolic disorders while navigating the inherent uncertainties of early-stage drug development.
Read more →QNTMFSD Pharma Provides Update on its Investment in Celly Nutrition Corp., a Company Launching a Product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption Toronto, ON
FSD Pharma has announced an increase in its investment in Celly Nutrition Corp., a company set to launch a new beverage aimed at expediting alcohol metabolism and enhancing recovery from alcohol consumption. The investment includes an amendment to a previous loan agreement, raising the loan principal to $1.3 million. Celly's product is expected to be introduced later this summer, and the partnership is viewed positively by both companies. However, there are inherent uncertainties related to drug development and regulatory approvals that could affect future outcomes.
Read more →QNTMFiled by newsfilecorp.com FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency TORONTO--(BUSINESS WIRE)-APRIL 7, 2024--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9) (" FSD Pharma "
FSD Pharma Inc. has received a notification from Nasdaq that it is currently not compliant with the minimum bid price requirement of $1.00 per share, as its Class B Shares closed below this threshold for 30 consecutive business days. The company has been granted 180 days to rectify this issue and can seek an extension if necessary. Despite this notification, FSD Pharma's business operations remain unaffected and it will continue to monitor its share prices and explore options for compliance. The notification does not impact its listings on the Canadian Securities Exchange or the Frankfurt Stock Exchange.
Read more →QNTMFSD Pharma announces Filing of Year-End 2023 Results Toronto, ON
FSD Pharma Inc. has announced the filing of its Annual Report on Form 20-F for the fiscal year ending December 31, 2023, which includes its audited financial results and management discussion. The company is working on developing innovative treatments for neurodegenerative disorders and alcohol misuse through its subsidiary, Lucid Psycheceuticals Inc., especially focusing on its lead compound, Lucid-MS. However, the report underscores the risks associated with early-stage drug development and the uncertainties tied to regulatory approval processes.
Read more →QNTMFSD Pharma signs the agreement with iNGENu CRO to conduct a clinical study to assess the safety and pharmacokinetics of multiple ascending doses of Lucid-21-302 (Lucid-MS) in healthy adults Toronto, ON
FSD Pharma has signed an agreement with iNGENu CRO to conduct a Phase 1 clinical study assessing the safety and pharmacokinetics of Lucid-21-302 (Lucid-MS) in healthy adults. This study builds upon a previous Phase 1 study that indicated the compound’s safety and tolerability. Lucid-21-302 is a novel neuroprotective compound aimed at treating multiple sclerosis and has shown potential in preventing demyelination in preclinical models. The company aims to advance its mission of developing innovative therapeutics for significant health challenges.
Read more →QNTMFSD Pharma Submits a Phase-1b Clinical Trial Application for Ethics Committee for its Proprietary Beverage unbuzzd Toronto, ON
FSD Pharma has submitted a Phase-1b Clinical Trial Application for its proprietary beverage, unbuzzd, aimed at enhancing cognition and alcohol metabolism. This application is currently under review by a human ethics review committee in Australia, with plans to start volunteer recruitment in April. The product, a fortified oral liquid, is designed to help restore mental alertness post-alcohol consumption and has garnered positive attention from industry experts. However, regulatory approval remains a key hurdle before the trial can officially begin.
Read more →QNTMFSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum Toronto, ON
FSD Pharma announced positive results from its first-in-human Phase-1 clinical study of Lucid-21-302 (Lucid-MS) at the ACTRIMS 2024 Forum. The findings indicated that Lucid-21-302 was safe and well-tolerated across the tested dosage range without serious adverse events. The drug, which has a unique neuroprotective mechanism, could play a significant role in preventing demyelination in conditions such as multiple sclerosis. FSD Pharma aims to further develop this promising candidate to improve treatment options for patients.
Read more →QNTMFSD Pharma Announces Debt Settlement Toronto, ON
FSD Pharma Inc. has announced the approval of a debt settlement amounting to $637,650, which will be settled through the issuance of 545,000 Class B Subordinate Voting shares at a price of $1.17 per share. Additionally, the board has approved 55,000 restricted share units to various consultants as part of its equity incentive plan. The company continues to focus on innovative biopharmaceutical developments, notably in neurodegenerative and metabolic disorders, with ongoing research on its lead compound, Lucid-MS. Despite these positive moves, the company also acknowledges several risks related to its future operations and drug development processes.
Read more →QNTMFSD Pharma Signs Agreement With Ingenu CRO to Conduct a Clinical Trial To Determine the Safety and Efficacy Effects of its Proprietary Blend Beverage unbuzzd Toronto, ON
FSD Pharma Inc. has announced an agreement with Ingenu CRO Pty Ltd to conduct a clinical trial assessing the safety and efficacy of its proprietary beverage, unbuzzd. This trial aims to determine if unbuzzd can help individuals sober up faster from alcohol intoxication. The collaboration highlights FSD Pharma's commitment to innovative biopharmaceutical solutions related to alcohol metabolism. The company continues to explore the potential of unbuzzd in both recreational and medical markets, emphasizing its focus on alcohol misuse disorders.
Read more →QNTMFSD Pharma Announces US ATM Offering Toronto, ON
FSD Pharma Inc. has announced an at-the-market offering agreement with H.C. Wainwright & Co. to sell Class B Subordinate Voting Shares, potentially raising up to $11.15 million. This offering will support various clinical studies and development programs, though the sales will occur at prevailing market prices. The company emphasizes that the ATM Offering carries risks, including uncertainty regarding regulatory approvals and the success of its drug candidates. FSD Pharma continues to focus on innovative treatments for neurodegenerative and metabolic disorders.
Read more →QNTMCourt of Appeal Dismisses Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Approximately $3 Million Toronto
FSD Pharma Inc. has received a favorable judgment from the Court of Appeal for Ontario, affirming an award of approximately CDN $2.81 million plus costs related to a failed appeal by Dr. Raza Bokhari. The court's decision confirms the previous arbitration ruling that dismissed Bokhari's claims of wrongful dismissal and awarded FSD Pharma its incurred fees. FSD Pharma is set to initiate collection processes for the awarded amount through a filing in the United States District Court. The company's ongoing development of innovative treatments underscores its commitment to neurodegenerative and metabolic disorder solutions.
Read more →QNTMFSD Pharma Announces Dr. Sanjiv Chopra is elected to FSD Pharma Board of Directors and Corporate Updates Toronto
FSD Pharma has announced the appointment of Dr. Sanjiv Chopra to its Board of Directors, replacing Nitin Kaushal, who has resigned. Dr. Chopra, an esteemed medical professional with extensive publications and experience, is expected to support FSD Pharma's mission and enhance its direction. Additionally, the company has engaged several consulting firms to improve market awareness and investor relations. These moves indicate FSD Pharma's proactive strategy in strengthening its leadership and promoting its innovative pharmaceutical solutions.
Read more →QNTMUpdate Provided on GBB Drink Lab, Inc. Litigation and Safety Shot TORONTO
FSD Pharma Inc. has provided an update regarding its litigation with GBB Drink Lab, Inc., which filed a lawsuit claiming breach of a nondisclosure agreement and trade secret misappropriation. The court recently denied FSD Pharma's Motion to Dismiss, allowing the discovery process to proceed. FSD Pharma adamantly denies the allegations, asserting that GBB's claims lack merit and were made in retaliation for its decision not to acquire GBB. Additionally, FSD Pharma has raised concerns about misleading public statements made by GBB's successor, Safety Shot, Inc., regarding its alcohol detoxification product.
Read more →QNTMFSD Pharma Files Final Base Shelf Prospectus to Replace Expired Base Shelf Prospectus and Form F-3 Registration Statement with the SEC Toronto
FSD Pharma has filed a final short form base shelf prospectus to replace its expired one and a registration statement with the SEC, enabling it to offer securities worth up to $50 million over the next 25 months. These actions aim to enhance financial flexibility for future financing opportunities. However, the registration statement is pending effectiveness, and the company acknowledges the early stage of its drug development programs, indicating potential risks. No securities have been authorized for sale at this time.
Read more →QNTMFORM 51-102F3 MATERIAL CHANGE REPORT Item 1: Name and Address of Company FSD Pharma Inc. (" FSD ") 199 Bay St., Suite 4000 Toronto, ON M5L 1A9 Item 2: Date of Material Change
FSD Pharma Inc. completed a spin-out transaction with Celly Nutrition Corp. on November 29, 2023. Under this plan, FSD distributed 45,712,529 common shares of Celly Nu to its securityholders, including holders of both Class A and Class B shares. The new shares are subject to resale restrictions until May 31, 2024. This arrangement was formalized following the terms of an agreement dated October 4, 2023.
Read more →QNTMFORM 51-102F3 MATERIAL CHANGE REPORT Item 1: Name and Address of Company FSD Pharma Inc. (the " Company ") 199 Bay Street, Suite 4000 Toronto, Ontario M5L 1A9 Item 2: Date of Material Change
FSD Pharma Inc. announced the appointment of Zeeshan Saeed as its new CEO, effective June 29, 2023. Saeed, who has served as President since 2019, takes over from Anthony Durkacz, the Interim CEO since July 2021. The leadership transition aims to streamline the company's operations and focus on the commercialization of its key products: UNBUZZD and Lucid-MS. However, the company is also suspending further clinical developments of some proprietary formulations as part of its strategy to maximize shareholder value.
Read more →QNTMFSD Pharma Inc. Announces Closing of Private Placement TORONTO
FSD Pharma Inc. has successfully closed a non-brokered private placement, issuing 24 Class A Shares at $1.90 each, yielding gross proceeds of $45.60. The funds raised will be used for general working capital purposes. Notably, key insiders participated in this offering, which signifies their belief in the company's prospects. The issued securities are under a statutory hold period per Canadian securities laws.
Read more →QNTMFORM 51-102F3 MATERIAL CHANGE REPORT Item 1: Name and Address of Company FSD Pharma Inc. (the " Company ") 199 Bay St., Suite 4000 Toronto, ON M5L 1A9 Item 2: Date of Material Change
FSD Pharma Inc. has completed a non-brokered private placement, issuing 24 Class A multiple voting shares at $1.90 each. The total gross proceeds from this Offering amounted to $45.60. The shares sold are subject to a hold period of four months and a day, with proceeds intended for general working capital. Insider participation in this Offering has been classified as a related party transaction, and the board of directors has determined it was in the Company's best interests to proceed without formal valuation or minority approval under applicable regulations.
Read more →QNTMFSD Pharma Inc. and Celly Nutrition Corp. Announce Completion of Plan of Arrangement TORONTO
FSD Pharma Inc. has announced the successful completion of its Plan of Arrangement with Celly Nutrition Corp. This plan involved the distribution of Celly Nutrition shares to FSD Pharma's shareholders as part of a strategic restructuring. The transaction allows shareholders to exchange their existing shares for new securities while also receiving shares in Celly Nu. However, the new shares are subject to resale restrictions until May 2024, which may impact liquidity for the investors.
Read more →QNTMUpdate Provided on GBB Drink Lab, Inc. Litigation and Safety Shot Previously known as Jupiter Wellness TORONTO
FSD Pharma has provided an update regarding its litigation with GBB Drink Lab, Inc., which has transitioned to trading as Jupiter Wellness, Inc. GBB alleges breaches of a non-disclosure agreement; however, FSD Pharma has denied these claims and filed a Motion to Dismiss. GBB's product claims regarding alcohol detoxification have been criticized for lacking scientific basis. Despite the legal challenges, FSD Pharma continues to advance its own alcohol detoxification product development.
Read more →QNTMFSD Pharma Inc. Obtains Final Order for Plan of Arrangement TORONTO
FSD Pharma Inc. has secured a final order from the Ontario Superior Court of Justice for its statutory plan of arrangement. This plan includes the distribution of shares from Celly Nutrition Corp. to its securityholders, comprising class A and class B shares as well as certain warrants. The arrangement is set to close by November 29, 2023, pending all customary conditions. Additionally, FSD Pharma has announced a non-brokered private placement of Class A Shares to existing shareholders.
Read more →QNTMFSD PHARMA ANNOUNCES DISTRIBUTION DATE FOR DISTRIBUTION OF CELLY SHARES PURSUANT TO PLAN OF ARRANGEMENT Toronto
FSD Pharma Inc. has announced that the distribution date for Celly shares pursuant to their planned arrangement is set for November 29, 2023. Shareholders of record as of November 28, 2023, will be eligible to receive one Celly Nu Share for each FSD Pharma Share held. The company anticipates distributing around 45.7 million Celly Nu Shares to its securityholders, with a special meeting scheduled for November 20, 2023, to vote on the arrangement, pending court approval on November 24, 2023.
Read more →QNTMFSD Pharma Files Supplement to Management Information Circular in Connection with Special Meeting to be Held on
FSD Pharma Inc. has filed a Supplement to its Management Information Circular in preparation for a special meeting scheduled for November 20, 2023. This Supplement includes additional disclosures concerning resale restrictions on certain shares distributed to securityholders. The company continues to advance its research into biopharmaceutical innovations, particularly the lead compound Lucid-MS, which aims to address neurodegenerative disorders. However, it acknowledges inherent uncertainties in drug development, as the process is still in early stages.
Read more →QNTMFiled by newsfilecorp.com FSD Pharma Inc. Condensed consolidated interim financial statements For the three and nine months ended
FSD Pharma Inc. reported its condensed consolidated interim financial statements for the three and nine months ended September 30, 2023. The company experienced a significant decrease in cash and cash equivalents and reported a net loss of $16,579,022 over the nine-month period. Additionally, accumulated deficits have grown, pointing to ongoing financial challenges. The increase in operating expenses further emphasizes the need for improved financial performance moving forward.
Read more →QNTMFSD PHARMA INC. 199 BAY ST., SUITE 4000 TORONTO, ON, M5L 1A9 www.fsdpharma.com SUPPLEMENT TO THE MANAGEMENT INFORMATION CIRCULAR DATED OCTOBER 20, 2023 This supplement dated
FSD Pharma Inc. has issued a supplement to their management information circular dated October 20, 2023, ahead of their upcoming special meeting of securityholders on November 20, 2023. This supplement clarifies restrictions on resale for the Celly Nu shares proposed to be distributed and extends the proxy submission deadline to November 17, 2023. Securityholders must be aware that these shares cannot be transferred until May 31, 2024, unless exceptions are made by Celly Nu. The intent is to provide shareholders additional time to consider their voting options.
Read more →QNTMFSD Pharma announces Interim Results from First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis. The Report Shows Compound to be Safe and Well Tolerated Toronto
FSD Pharma has announced positive interim results from its first-in-human clinical trial for Lucid-MS, a treatment for Multiple Sclerosis. The interim report indicates that the drug was safe and well tolerated in healthy volunteers, with encouraging pharmacokinetic parameters. The company plans to continue the development of Lucid-MS, addressing a significant unmet need in treatments for progressive MS. The next cohort results are anticipated by the end of the month, signaling ongoing development momentum.
Read more →QNTMARRANGEMENT AGREEMENT THIS ARRANGEMENT AGREEMENT (" Agreement ") is made as of the 4 th day of October, 2023. BETWEEN: FSD PHARMA INC., a corporation incorporated pursuant to the laws of the Province of Ontario, Canada.
On October 4, 2023, FSD Pharma Inc. entered into an arrangement agreement with Celly Nutrition Corp. This agreement outlines a reorganization transaction under the Ontario Business Corporations Act, designed to ensure that shareholders of FSD Pharma receive fair consideration for their shares. The board has deemed this transaction to be in the best interests of the corporation, signaling a potential strategic alignment and future growth opportunities.
Read more →QNTMFORM 51-102F3 MATERIAL CHANGE REPORT Item 1: Name and Address of Company FSD Pharma Inc. (the " Corporation ") 199 Bay St., Suite 4000 Toronto, ON M5L 1A9 Item 2: Date of Material Change
FSD Pharma Inc. announced a definitive arrangement agreement with Celly Nutrition Corp. to distribute part of its shareholdings in Celly Nu to its shareholders. A total of 45,714,621 shares will be distributed, pending approval from shareholders at a special meeting scheduled for November 20, 2023. This arrangement also outlines that FSD Pharma will retain approximately 154,285,379 shares of Celly Nu. The plan is subject to regulatory and shareholder approvals, indicating risks in completing the transaction.
Read more →QNTMFSD Pharma Files Preliminary Base Shelf Prospectus to Replace Expired Base Shelf Prospectus Toronto
FSD Pharma Inc. has filed a preliminary base shelf prospectus in Toronto, aiming to replace its expired one. This new prospectus will allow the company to potentially raise up to USD$50 million over the next 25 months through the sale of various securities. While this move provides flexibility for financing, it does not guarantee that any securities will be sold during this period. Additionally, the company acknowledges the risks associated with drug development and the uncertainties that may impact future outcomes.
Read more →QNTMFSD Pharma Files Management Information Circular for Proposed Arrangement with Celly Nu Toronto
FSD Pharma Inc. has filed a management information circular regarding a proposed arrangement with Celly Nutrition Corp., with a special meeting set for November 20, 2023. This arrangement includes plans to distribute a portion of FSD Pharma's holdings of Celly Nu to certain securityholders. The circular outlines important information related to the arrangement and voting procedures. However, the company cautions that completion of the arrangement is not guaranteed, and investing in Celly is considered highly speculative.
Read more →QNTMFSD Pharma Rebuts Claims of GBB Drink Lab now acquired by Jupiter Wellness Inc. Trading under the symbol (NASDAQ: JUPW) TORONTO--(BUSINESS WIRE)
FSD Pharma has officially rebutted claims from GBB Drink Lab, now part of Jupiter Wellness, regarding alleged breaches of a nondisclosure agreement and trade secret misappropriation. FSD Pharma argues that the claims are unfounded and emphasizes its commitment to developing innovative products for alcohol detoxification. As tensions rise, FSD Pharma is prepared to defend its position legally while continuing its product development efforts under strict regulatory standards.
Read more →QNTMFiled by newsfilecorp.com FSD Pharma Signs Definitive Agreement to Launch UNBUZZD, a Revolutionary Rapid Alcohol Detoxification Drink Launch in the Consumer Market to be Led by Former Executives from Coca-Cola (NYSE: KO)
FSD Pharma has announced a definitive agreement with Celly Nutrition Inc. to launch UNBUZZD, a rapid alcohol detoxification beverage. The product aims to address a growing market, as the hangover cure products sector is expected to see significant growth in the coming years. Key figures from prominent companies like Coca-Cola and Celsius Holdings are leading the commercialization efforts. However, UNBUZZD still requires scientific testing, and no clinical trials have been conducted to validate its effectiveness.
Read more →QNTMArbitration Panel Finds that Syneos Health (NASDAQ: SYNH) Failed to Use Commercially Reasonable Efforts in Conducting its Trial for FSD 201 TORONTO--(BUSINESS WIRE)
The Arbitration Panel has ruled that Syneos Health did not use commercially reasonable efforts during its trial for FSD 201, which resulted in poor patient enrollment. Despite Syneos seeking nearly $4 million from FSD Pharma for damages, the panel awarded them about $1.7 million for unpaid invoices. This decision allows FSD Pharma to demonstrate resilience against larger contract research organizations, marking a notable victory. FSD has made it clear they will not be intimidated and seeks to connect with others who may have similar grievances against Syneos.
Read more →QNTMFSD Pharma Retains Christian Attar Law and Team of Experts to Lead Preliminary Investigation of Possible Naked Short Selling and Manipulation in its stock TORONTO--(BUSINESS WIRE)
FSD Pharma has retained Christian Attar Law and a team to investigate possible naked short selling and stock manipulation involving its shares. This investigation will involve collaboration with legal partners and submission of evidence to regulatory authorities. The company is focused on developing innovative biotechnology solutions while managing the potential risks associated with this legal action and market concerns.
Read more →QNTMFSD Pharma Appoints Zeeshan Saeed as Chief Executive Officer, Anthony Durkacz to Serve as Executive Co-Chairman of the Board of Directors Appointment culminates multi-year succession plan as FSD focuses on commercializat
FSD Pharma has appointed Zeeshan Saeed as its new CEO, succeeding Anthony Durkacz, who will continue as Executive Co-Chairman. This leadership change is part of a multi-year succession plan as the company focuses on commercializing two key products: UNBUZZD, aimed at addressing alcohol misuse, and Lucid-MS, targeting neurodegenerative disorders. Under Saeed's direction, FSD will streamline operations, putting on hold other clinical developments to concentrate resources where they expect the best chance for revenue growth. The leadership believes this strategy will enhance shareholder value.
Read more →QNTMFiled by newsfilecorp.com FSD Pharma Inc. Condensed consolidated interim financial statements For the three and six months ended
FSD Pharma Inc. reported its financial results for the second quarter ended June 30, 2023, experiencing continued losses in both net income and comprehensive loss. The company recorded a net loss of $5.49 million in Q2 2023, compared to a $4.42 million loss in Q2 2022, contributing to a total accumulated deficit of over $155 million. Additionally, cash and cash equivalents have significantly declined, impacting the company's liquidity position. FSD Pharma has also made a strategic decision to terminate ongoing research and development for its compound FSD-PEA.
Read more →QNTMFSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders TORONTO--(BUSINESS WIRE)
FSD Pharma Inc. held its annual general and special meeting where significant shareholder decisions were made. The meeting saw high approval rates for the election of directors, with most receiving upwards of 84% votes in favor. The re-appointment of MNP LLP as auditors affirms trust in the company's financial practices. Additionally, shareholders approved existing equity plans and the possibility of changing the company's name and branding moving forward.
Read more →QNTMFSD Pharma Announces Agreement to Grant Exclusive Rights to Revolutionary Recreational Alcohol Misuse Technology JOHN DUFFY, COCA-COLA VETERAN TEAMS UP WITH GERRY DAVID, FORMER CELSIUS CEO, AND MARKETING GURU KEVIN HARRI
FSD Pharma has entered into a non-binding agreement with Celly Nutrition Inc. to grant exclusive rights to its alcohol misuse technology for recreational applications. The partnership includes significant figures from marketing and sales, such as John Duffy, who will lead Celly Nutrition as CEO, and Gerry David as Chairman. FSD will receive 100 million shares and a 7% royalty on revenue from any resulting products. The agreement represents a strategic shift, allowing the company to focus on both medical and recreational markets.
Read more →QNTMFSD Pharma Appoints Former Ontario Minister of Health Doctor Eric Hoskins to Board of Directors TORONTO--(BUSINESS WIRE)
FSD Pharma has appointed Dr. Eric Hoskins, a former Ontario Minister of Health, to its Board of Directors. This strategic move follows the resignation of Donal Carroll and is intended to enhance the company's oversight in drug development. Dr. Hoskins, who has nearly four decades of experience in healthcare, expressed his commitment to FSD's innovative initiatives in treating various diseases. The company believes his expertise will be instrumental in navigating the evolving biopharmaceutical landscape.
Read more →QNTMFiled by newsfilecorp.com FSD Pharma Inc. Condensed consolidated interim financial statements For the three months ended
FSD Pharma has released its condensed consolidated interim financial statements for the three months ending March 31, 2023. The report shows a significant increase in net losses compared to the same period in 2022, with total losses reported as $9,957,529. Additionally, the company's cash reserves have declined considerably, a point that raises concerns about its operational viability. This financial performance indicates mounting challenges for the company in managing its expenses and sustaining its research and development initiatives.
Read more →QNTMFSD Pharma Announces Receipt of Court Action and Update on Spin-Out and Distribution TORONTO--(BUSINESS WIRE)
FSD Pharma announced that it has received a court complaint from GBB Drink Lab, alleging breach of a nondisclosure agreement and misappropriation of trade secrets. The complaint was filed on May 1, 2023, and delivered to FSD on May 9, 2023. FSD Pharma believes the allegations are without merit and plans to vigorously defend itself. Additionally, the company is still working on its Spin-Out Transaction, but necessary documentation for shareholder approval will not be ready in time for the June 29, 2023 meeting, necessitating a postponement.
Read more →QNTMFSD Pharma Awarded $2.81 Million in Cost Awards From Dr. Raza Bokhari TORONTO--(BUSINESS WIRE)
FSD Pharma has been awarded approximately $2.81 million in costs of arbitration ruled by Justice J. Douglas Cunningham, following a dismissal of a wrongful dismissal claim by former CEO Dr. Raza Bokhari. The costs were detailed as including legal fees, disbursements, and HST, reinforcing the company's financial position amid ongoing disputes. FSD Pharma remains hopeful for a resolution as it looks to advance its biotechnology initiatives.
Read more →QNTMFSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second Cohort TORON
FSD Pharma has announced the successful completion of dosing the first cohort in its Phase I clinical trial of Lucid-MS, a new drug candidate aimed at treating Multiple Sclerosis. Following the completion, the safety review committee has recommended moving forward with dosing the second cohort. Lucid-MS is a first-in-class compound targeting hypercitrullination and has demonstrated potential in preclinical models to prevent myelin degradation, an important factor in MS progression. The trial involves a randomized, double-blind study with healthy volunteers to evaluate safety and pharmacokinetics.
Read more →QNTMFSD Pharma to Present at Sidoti Virtual Investor Conference May 10-11 TORONTO--(BUSINESS WIRE)
FSD Pharma Inc. has announced its participation in the Sidoti Virtual Investor Conference scheduled for May 10-11, 2023. The company's President Zeeshan Saeed and CEO Dr. Lakhsmi Kotra will present and host meetings with investors. This event presents an opportunity for FSD Pharma to discuss its innovative approaches in biopharmaceuticals and its pipeline of drug candidates focused on neurodegenerative and mental health disorders. Registration for the conference is open to all interested investors at no cost.
Read more →QNTMFSD Pharma Achieves Milestone in Completion of Dosing of Sentinel Subjects in First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis TORONTO--(BUSINESS WIRE)
FSD Pharma has announced the completion of sentinel dosing in its Phase I clinical trial for Lucid-MS, a first-in-class oral treatment for Multiple Sclerosis. This milestone is the result of over a decade of research and development aimed at offering safer and more effective options for patients. Lucid-MS has demonstrated potential in preclinical models to prevent myelin degradation and promote recovery in MS, addressing the significant unmet needs in current treatments.
Read more →QNTMFSD Pharma Announces Plan to Spin-Out Subsidiary as Distribution to Shareholders; Shareholder Meeting Scheduled for
FSD Pharma has announced a plan to spin out a subsidiary, Pubco, as part of a transaction intended to enhance shareholder value. Shareholders will receive shares in Pubco in proportion to their holdings in FSD Pharma. The spin-out transaction is expected to be finalized in July 2023, following a shareholder vote scheduled for June 29, 2023. However, the completion of the transaction is subject to standard regulatory approvals and other conditions.
Read more →QNTMFSD Pharma Announces Filing of Year-End 2022 Results TORONTO--(BUSINESS WIRE)
FSD Pharma Inc. has announced the filing of its Annual Report on Form 20-F for the year ending December 31, 2022, including financial results and management analysis. The company is focused on the development of several drug candidates aimed at treating neurodegenerative and inflammatory disorders. However, the document highlights the inherent risks and uncertainties in drug development, emphasizing that current projects are in early stages and may face significant obstacles.
Read more →QNTMFSD Pharma Adds Former Celsius Holdings CEO Gerry David to Board of Advisors Previously Headed Successful Global Expansion Resulting in Dramatic Increase in Sales and 35-Fold Increase in Shareholder Value for Drink Busin
FSD Pharma announced the appointment of Gerry David, the former CEO of Celsius Holdings, to its Advisory Board. David is recognized for his successful turnaround of Celsius, leading to a significant increase in sales and shareholder value. His expertise in business development and strategic planning is expected to enhance FSD Pharma's efforts in developing products targeting alcohol misuse. The company, involved in biopharmaceutical solutions for various disorders, aims to leverage David's background for future growth and commercialization.
Read more →QNTMFSD Pharma Announces Its Australian Entity Receives Approval to Proceed With Phase 1 Clinical Trial of Lucid-201, a Candidate for the Potential Treatment of Major Depressive Disorder TORONTO--(BUSINESS WIRE)
FSD Pharma has announced that its Australian subsidiary has received approval from The Alfred Ethics Committee to initiate a Phase 1 clinical trial for its drug candidate Lucid-201, aimed at treating Major Depressive Disorder. The approval supports the development of Lucid-Psych, a psychoactive molecule that could offer a novel therapeutic approach to mental health treatment. FSD Pharma's CEO expressed optimism regarding the treatment's safety and the potential to provide effective alternatives to existing antidepressants, which often have significant side effects. However, the company acknowledges the inherent risks in drug development, particularly given the early stage of their clinical trials.
Read more →QNTMFSD Pharma (Symbol: HUGE) Renews Shareholder Intelligence Services to Investigate Possible Naked Short Selling and Appeals to The Regulators and Oversight Bodies to Look Into The Short Selling Activity Of Its Stock TORON
FSD Pharma, listed as HUGE, has renewed its agreement with ShareIntel to investigate potential naked short selling of its stock. The company has faced numerous shareholder inquiries regarding discrepancies in trading activity that have gone largely unanswered by broker-dealers. As part of its fiduciary duty, FSD Pharma is exploring legal options to address these issues and ensure transparency for its investors. Management emphasizes their commitment to addressing shareholder concerns and advocating for better market practices.
Read more →QNTMOriginal "Shark" and Iconic Entrepreneur Kevin Harrington Joins FSD Pharma Advisory Board Harrington to provide strategic guidance on FSD Pharma's pipeline including recently announced alcohol misuse R&D program TORONTO-
FSD Pharma Inc. has announced the appointment of Kevin Harrington to its Advisory Board. Known for his role on 'Shark Tank' and extensive entrepreneurial experience, Harrington will provide strategic guidance to the company, particularly focusing on their research and development program for alcohol misuse. The company expects Harrington's involvement to bolster their pipeline of innovative therapeutic assets. Additionally, FSD Pharma is taking steps to expand its Advisory Board further.
Read more →QNTMFSD Pharma Presenting Two Scientific Posters on Preclinical Toxicology and Efficacy Data of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2023 Forum FSD Pharma r
FSD Pharma Inc. announced that it will present two scientific posters on its MS drug candidate Lucid-21-302 (Lucid-MS) at the upcoming ACTRIMS 2023 Forum. The presentations will cover preclinical toxicology and efficacy data, which have shown the drug's neuroprotective effects in disease models. Additionally, FSD Pharma has received regulatory approval to initiate a Phase 1 clinical trial in Canada. This participation underscores the company's commitment to advancing treatments for multiple sclerosis.
Read more →QNTMFSD Pharma Regains Compliance with NASDAQ Continued Listing Requirements TORONTO--(BUSINESS WIRE)
FSD Pharma announced that it has regained compliance with NASDAQ's continued listing requirements by meeting the minimum bid price of $1.00 per share. This follows a notification from NASDAQ regarding a failure to maintain the required price, which has now been resolved. The validation comes after the stock price has consistently exceeded the minimum for 10 consecutive business days. FSD Pharma is advancing several drug candidates, including treatments for neurodegenerative and mental health disorders.
Read more →QNTMFSD Pharma Launches A New Research and Development Program Targeting Unmet Medical Needs for Alcohol Misuse TORONTO--(BUSINESS WIRE)
FSD Pharma has announced the initiation of a new research and development program focused on addressing unmet medical needs related to alcohol misuse. This program aims to provide new treatment options to enhance recovery in patients presenting with alcohol intoxication. The initiative leverages the existing expertise of its advisory team and aims to navigate the challenges faced in managing substance misuse disorders. However, the development processes are still in early stages, highlighting the inherent risks associated with drug development.
Read more →QNTMFSD Pharma Receives Regulatory Clearance for Its Proposed Phase-1 Clinical Trial of Lucid-21-302 (Lucid-MS), First-in-Class Multiple Sclerosis Drug Candidate TORONTO--(BUSINESS WIRE)
FSD Pharma has received a No Objection Letter from Health Canada for its proposed Phase-1 clinical trial of Lucid-21-302, a novel drug targeting Multiple Sclerosis. The trial aims to evaluate the safety and tolerability of Lucid-MS, which is a neuroprotective compound with a unique mechanism of action. Preclinical studies suggest it could prevent myelin degradation, a critical factor in MS progression. This marks a significant step for FSD Pharma in addressing the need for innovative and non-immunomodulatory treatment options for MS.
Read more →QNTMRecruiting Underway in FSD Pharma's Phase 2 Trial of FSD-PEA (FSD201) for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD) TORONTO--(BUSINESS WIRE)
FSD Pharma has begun recruiting patients for its Phase 2 clinical trial of FSD201, aimed at treating chronic pain associated with idiopathic MCAS. The study will take place at multiple sites across the USA and Canada, with a primary focus on evaluating the pain relief efficacy of the drug. FSD201, an anti-inflammatory compound, has already completed a Phase 1 trial and received designation as a new molecular entity, indicating its potential market exclusivity. The trial aims to enroll a total of 60 patients, with a significant emphasis on improving the quality of life for those suffering from chronic conditions related to mast cell activation syndrome.
Read more →QNTMFSD Pharma submits its phase-1 Clinical Trial Application for Lucid-MS (Lucid-21-302) for first-in-human safety and tolerability investigation Company Seeking to Initiate Phase 1 Clinical Trial for its First-in-Class Mul
FSD Pharma has submitted a Clinical Trial Application for its drug candidate Lucid-MS, aimed at treating Multiple Sclerosis. This candidate is described as a first-in-class neuroprotective compound, which has shown potential in preclinical models to prevent myelin degradation and promote recovery in MS. The company is eager to initiate its Phase-1 clinical trial, highlighting the significant need for effective treatments in the MS community.
Read more →QNTMFSD Pharma Announces Share Repurchase Program TORONTO--(BUSINESS WIRE)
FSD Pharma Inc. has announced a new share repurchase program authorized by its Board of Directors, allowing the company to buy back up to 1,925,210 Subordinate Voting Shares over the next year. This initiative aims to leverage excess cash reserves to enhance shareholder value while pursuing the company's growth objectives. The repurchase is part of the company's strategy to address the perceived undervaluation of its stock, signaling confidence in its portfolio and future potential. The initiative may commence as early as January 18, 2023.
Read more →QNTMFSD Pharma Inc Incorporates New Subsidiary to Capitalize on Drug Development Incentives in Australia FSD Pharma Inc Announces Three Key Additions to Scientific and Clinical Expert Committee FSD Pharma Inc Announces It Is
FSD Pharma Inc. has announced the formation of a new subsidiary in Australia aimed at leveraging government incentives for drug development. The company also appointed three distinguished experts to its Scientific and Clinical Expert Committee, which is expected to enhance its research capabilities. Additionally, FSD Pharma is investigating new products targeting acute medical needs related to substance abuse, signaling its commitment to addressing significant health challenges. Overall, these strategic moves indicate FSD Pharma's intent to strengthen its product pipeline and expand its market presence.
Read more →QNTMFSD Pharma to Attend 41st Annual J.P. Morgan Healthcare Conference 2023 TORONTO--(BUSINESS WIRE)
FSD Pharma Inc. announced its attendance at the 41st Annual J.P. Morgan Healthcare Conference from January 9-12, 2023, in San Francisco. Key executives, including CEO Dr. Lakshmi P. Kotra, will represent the company, which focuses on developing innovative biopharmaceutical products. FSD Pharma has multiple drug candidates under development, including FSD201 for inflammatory diseases and other compounds for mental health and neurodegenerative disorders. The conference serves as a key networking platform for industry leaders and emerging companies.
Read more →QNTMFSD Pharma Announces Changes to the Board of Directors TORONTO--(BUSINESS WIRE)
FSD Pharma Announces Changes to the Board of Directors TORONTO--(BUSINESS WIRE)--November 28, 2022--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biot
Read more →QNTMFSD Pharma Announces Arbitrator Dismisses Claims by Former CEO, Dr. Raza Bokhari TORONTO--(BUSINESS WIRE)
FSD Pharma Announces Arbitrator Dismisses Claims by Former CEO, Dr. Raza Bokhari TORONTO--(BUSINESS WIRE)--November 10, 2022--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of i
Read more →QNTMFSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency TORONTO--(BUSINESS WIRE)
FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency TORONTO--(BUSINESS WIRE)--September 29, 2022--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio
Read more →QNTMFSD Pharma Participating in H.C. Wainwright 24th Annual Global Investment Conference, On-Demand Presentation Available TORONTO--(BUSINESS WIRE)
FSD Pharma Participating in H.C. Wainwright 24th Annual Global Investment Conference, On-Demand Presentation Available TORONTO--(BUSINESS WIRE)--September 12, 2022--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical compan
Read more →QNTMFDA and Health Canada Clear IND for FSD Pharma to Proceed with Phase 2 Trial of FSD201 for Nociplastic Pain Associated with Idiopathic Mast Cell Activation Syndrome TORONTO--(BUSINESS WIRE)
FDA and Health Canada Clear IND for FSD Pharma to Proceed with Phase 2 Trial of FSD201 for Nociplastic Pain Associated with Idiopathic Mast Cell Activation Syndrome TORONTO--(BUSINESS WIRE)--September 6, 2022--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) ("FSD Pharma"
Read more →QNTMFSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent On Novel Formulations of Palmitoylethanolamide, Presents Preclinical Toxicology Results at an International Symposium TORONTO--(BUSINESS WIRE)
FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent On Novel Formulations of Palmitoylethanolamide, Presents Preclinical Toxicology Results at an International Symposium TORONTO--(BUSINESS WIRE)--July 13, 2022--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) ("FS
Read more →QNTMFSD Pharma Inc. Announces Results of Annual General Meeting of Shareholders And Other Corporate Updates TORONTO--(BUSINESS WIRE)
FSD Pharma Inc. Announces Results of Annual General Meeting of Shareholders And Other Corporate Updates TORONTO--(BUSINESS WIRE)--June 27, 2022--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to b
Read more →QNTMFSD Pharma Files Investigational New Drug Application ("IND") with FDA and Health Canada for Phase-2 Trial of FSD-201 for an Inflammatory disorder and Provides Corporate Updates TORONTO--(BUSINESS WIRE)
FSD Pharma Files Investigational New Drug Application ("IND") with FDA and Health Canada for Phase-2 Trial of FSD-201 for an Inflammatory disorder and Provides Corporate Updates TORONTO--(BUSINESS WIRE)--May 31, 2022--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) ("FSD
Read more →QNTMFSD Pharma Issues Circular, Adopts Incentive Plan and Grants PSUs TORONTO--(BUSINESS WIRE)
FSD Pharma Issues Circular, Adopts Incentive Plan and Grants PSUs TORONTO--(BUSINESS WIRE)--May 24, 2022--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets and biote
Read more →QNTMFiled by newsfilecorp.com FSD PHARMA INC. NOTICE OF ANNUAL GENERAL MEETING OF THE SHAREHOLDERS TO BE HELD ON JUNE 23, 2022 AND MANAGEMENT INFORMATION CIRCULAR DATED: MAY 20, 2022 FSD PHARMA INC. 199 Bay St., Suite 4000 T
ANNUAL GENERAL MEETING OF THE SHAREHOLDERS MANAGEMENT INFORMATION CIRCULAR 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN that the annual general meeting of the shareholders (the "Meeting") of FSD Phar
Read more →QNTMFSD Pharma Closes CAD$16.4 Million Sale of Non-Core Assets Nets CAD$15,480,780 cash in non-dilutive capital Current cash position of approximately CAD$50 million or approximately CAD $1.30 per share with only 38.4 millio
FSD Pharma Closes CAD$16.4 Million Sale of Non-Core Assets Nets CAD$15,480,780 cash in non-dilutive capital Current cash position of approximately CAD$50 million or approximately CAD $1.30 per share with only 38.4 million shares issued Profit realized on the sale of the non-co
Read more →QNTMFSD Pharma Announces Dismissal of Derivative Complaint TORONTO--(BUSINESS WIRE)
FSD Pharma Announces Dismissal of Derivative Complaint TORONTO--(BUSINESS WIRE)--May 6, 2022--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions,
Read more →QNTMFiled by newsfilecorp.com MAY 3, 2022 TO ALL APPLICABLE EXCHANGES AND COMMISSIONS: RE: FSD PHARMA INC. Confirmation of Notice of Record and Meeting Dates We are pleased to confirm that Notice of Record and Meeting Date w
TO ALL APPLICABLE EXCHANGES AND COMMISSIONS: We are pleased to confirm that Notice of Record and Meeting Date was sent to The Canadian Depository for Securities. We advise the following with respect to the upcoming Annual General Meeting of Security Holders for the subject issue
Read more →QNTMFSD Pharma Announces Engagement with Tekkfund Capital and Share Issuance to Crystal Research Associates TORONTO--(BUSINESS WIRE)
FSD Pharma Announces Engagement with Tekkfund Capital and Share Issuance to Crystal Research Associates TORONTO--(BUSINESS WIRE)--May 2, 2022--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to bui
Read more →QNTMFSD Pharma Appoints Julia Levy Award Recipient David Allan and Dr. John McGraw to Advisory Board Mr. Allan, the 2017 winner of the prestigious Julia Levy Award, to collaborate with 2021 Julia Levy Award winner Dr. Lakshm
FSD Pharma Appoints Julia Levy Award Recipient David Allan and Dr. John McGraw to Advisory Board Mr. Allan, the 2017 winner of the prestigious Julia Levy Award, to collaborate with 2021 Julia Levy Award winner Dr. Lakshmi P. Kotra, CEO of FSD Pharma subsidiary Lucid TORONTO--(B
Read more →QNTMFSD Pharma Announces Cancellation of Certain Shares Issued to Former Chief Executive Officer Dr. Raza Bokhari TORONTO--(BUSINESS WIRE)
FSD Pharma Announces Cancellation of Certain Shares Issued to Former Chief Executive Officer Dr. Raza Bokhari TORONTO--(BUSINESS WIRE)--April 8, 2022--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a life sciences holding company dedicate
Read more →QNTMFSD Pharma Issues Corporate Updates TORONTO--(BUSINESS WIRE)
FSD Pharma Issues Corporate Updates TORONTO--(BUSINESS WIRE)--April 6, 2022--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced toda
Read more →QNTMFSD Pharma Announces Filing of Year-End 2021 Results TORONTO--(BUSINESS WIRE)
FSD Pharma Announces Filing of Year-End 2021 Results TORONTO--(BUSINESS WIRE)--March 31, 2022--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions
Read more →QNTMFSD Pharma Announces Executive Informational Overview Report Produced by Crystal Research Associates LLC Research report reviews FSD Pharma's drug development pipeline and operational milestones TORONTO--(BUSINESS WIRE)
FSD Pharma Announces Executive Informational Overview Report Produced by Crystal Research Associates LLC Research report reviews FSD Pharma's drug development pipeline and operational milestones TORONTO--(BUSINESS WIRE)--March 15, 2022--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE
Read more →QNTMFSD Pharma Announces Agreement for Sale of Cobourg Facility for CAD$16,500,000 TORONTO--(BUSINESS WIRE)
FSD Pharma Announces Agreement for Sale of Cobourg Facility for CAD$16,500,000 TORONTO--(BUSINESS WIRE)--February 25, 2022--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio o
Read more →QNTMFSD Pharma Announces Launch of New Corporate Website New Website Shares FSD's Unique Drug Pipeline and Vision to Improve the Quality of Life for Patients Suffering from Brain & Inflammatory Disorders TORONTO--(BUSINESS W
FSD Pharma Announces Launch of New Corporate Website New Website Shares FSD's Unique Drug Pipeline and Vision to Improve the Quality of Life for Patients Suffering from Brain & Inflammatory Disorders TORONTO--(BUSINESS WIRE)--January 20, 2022--FSD Pharma Inc. (NASDAQ: HUGE) (CS
Read more →QNTMFSD Pharma Congratulates Dr. Eleanor Fish on Being Named to the Order of Canada TORONTO--(BUSINESS WIRE)
FSD Pharma Congratulates Dr. Eleanor Fish on Being Named to the Order of Canada TORONTO--(BUSINESS WIRE)--January 18, 2022--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio o
Read more →QNTMFSD Pharma to Present at the H.C. Wainwright Bioconnect Conference on January 10-13 th TORONTO--(BUSINESS WIRE)
FSD Pharma to Present at the H.C. Wainwright Bioconnect Conference on January 10-13 th TORONTO--(BUSINESS WIRE)--January 4, 2022--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portf
Read more →QNTMFSD Pharma Establishes New Regulatory Advisory Board with the Appointment of Joga Gobburu, Ph.D., and Mary Melnyk, Ph.D., as Members Regulatory Advisory Board will oversee the drug development pathway for FSD Pharma's cl
FSD Pharma Establishes New Regulatory Advisory Board with the Appointment of Joga Gobburu, Ph.D., and Mary Melnyk, Ph.D., as Members Regulatory Advisory Board will oversee the drug development pathway for FSD Pharma's clinical drug candidates TORONTO--(BUSINESS WIRE)--December
Read more →QNTMFSD Pharma to Present at the H.C. Wainwright 2 nd Annual Psychedelics Virtual Conference on December 6 th TORONTO--(BUSINESS WIRE)
FSD Pharma to Present at the H.C. Wainwright 2 nd Annual Psychedelics Virtual Conference on December 6 th TORONTO--(BUSINESS WIRE)--December 3, 2021--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated
Read more →QNTMFSD Pharma Unveils Videos Demonstrating Positive Effects of Lucid-MS in Treating Multiple Sclerosis in Pre-Clinical Models (Mouse Models) TORONTO--(BUSINESS WIRE)
FSD Pharma Unveils Videos Demonstrating Positive Effects of Lucid-MS in Treating Multiple Sclerosis in Pre-Clinical Models (Mouse Models) TORONTO--(BUSINESS WIRE)--December 2, 2021--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) ("FSD Pharma" or the "Company"), a life sci
Read more →QNTMFSD Pharma Expands Research and Clinical Advisory Board with Appointment of World-Renowned Immunologist and Cytokine Expert Dr. Eleanor N. Fish TORONTO--(BUSINESS WIRE)
FSD Pharma Expands Research and Clinical Advisory Board with Appointment of World-Renowned Immunologist and Cytokine Expert Dr. Eleanor N. Fish TORONTO--(BUSINESS WIRE)--November 16, 2021--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) ("FSD Pharma" or the "Company"), a l
Read more →QNTMFiled by newsfilecorp.com FSD PHARMA INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS As used in this management's discussion and analysis of financial condition and results of o
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF As used in this management's discussion and analysis of financial condition and results of operations ("MD&A"), unless the context indicates or requires otherwise, all references to the "Company", "FSD",
Read more →QNTMFSD Pharma Signs Agreement with Covar Pharmaceuticals to Support the Development of Lucid-PSYCH TORONTO--(BUSINESS WIRE)
FSD Pharma Signs Agreement with Covar Pharmaceuticals to Support the Development of Lucid-PSYCH TORONTO--(BUSINESS WIRE)--October 19, 2021--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to buildin
Read more →QNTMFSD Pharma Announces Engagement with Capital Markets Communications Providers and Market Maker TORONTO--(BUSINESS WIRE)
FSD Pharma Announces Engagement with Capital Markets Communications Providers and Market Maker TORONTO--(BUSINESS WIRE)--September 22, 2021--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to buildi
Read more →QNTMFiled by newsfilecorp.com FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Company FSD Pharma Inc. (the " Company ") 199 Bay Street Suite 4000 Toronto, Ontario M5L 1A9 Item 2 Date of Material Change
MATERIAL CHANGE REPORT Item 1 Name and Address of Company FSD Pharma Inc. (the "Company") Item 2 Date of Material Change A news release (the "News Release") describing the material change was issued by the Company through the facilities of Business Wire and subsequently filed
Read more →QNTMMASTER AGREEMENT THIS AGREEMENT made as of the 25th day of August, 2021 AMONG: FSD PHARMA INC. a corporation con incorporated under the laws of the province of Ontario (" FSD ") - and - 2861435 ONTARIO INC. a corporation
THIS AGREEMENT made as of the 25th day of August, 2021 a corporation con incorporated under the laws of the province of Ontario 2861435 ONTARIO INC. a corporation incorporated under the laws of the province of Ontario LUCID PSYCHECEUTICALS INC. a corporation incorporated und
Read more →QNTMFSD Pharma Announces Definitive Agreement to Acquire Lucid Psycheceuticals Acquisition Advances Company's Strategic Plan Toward a Diversified Novel Drug Development Pipeline in Psychedelics and Medical Cannabis TORONTO--
FSD Pharma Announces Definitive Agreement to Acquire Lucid Psycheceuticals Acquisition Advances Company's Strategic Plan Toward a Diversified Novel Drug Development Pipeline in Psychedelics and Medical Cannabis TORONTO--(BUSINESS WIRE)--August 25, 2021--FSD Pharma Inc. (NASDAQ:
Read more →QNTMFSD Pharma Inc. Announces Termination of FSD-201 Phase 2 Clinical Trial However, will continue to evaluate other potential commercial opportunities with FSD-201 TORONTO--(BUSINESS WIRE)
FSD Pharma Inc. Announces Termination of FSD-201 Phase 2 Clinical Trial However, will continue to evaluate other potential commercial opportunities with FSD-201 TORONTO--(BUSINESS WIRE)--August 24, 2021--FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) (FRA:0K9) (the "Company" or "FSD"
Read more →QNTMFSD Pharma Inc. Announces Termination of Chief Executive Officer Dr. Raza Bokhari for Cause Appoints Anthony Durkacz as Interim Chief Executive Officer and Reinstates Zeeshan Saeed as President TORONTO--(BUSINESS WIRE)
FSD Pharma Inc. Announces Termination of Chief Executive Officer Dr. Raza Bokhari for Cause Appoints Anthony Durkacz as Interim Chief Executive Officer and Reinstates Zeeshan Saeed as President TORONTO--(BUSINESS WIRE)--July 27, 2021--FSD Pharma Inc. (Nasdaq: HUGE) (CSE:HUGE) (
Read more →QNTMFSD Pharma Inc. Appoints a New Independent Director TORONTO--(BUSINESS WIRE)
FSD Pharma Inc. Appoints a New Independent Director TORONTO--(BUSINESS WIRE)--June 3, 2021--FSD Pharma Inc. (Nasdaq: HUGE) (CSE:HUGE) (FRA:0K9) (the "Company" or "FSD") is pleased to announce the appointment of Mr. Adnan Bashir as an independent member of its Board of Directors
Read more →QNTMFSD Pharma Inc. Announces Results of the Annual General and Special Meeting of Shareholders - Nominees of the Concerned Shareholders Elected to the Board of Directors TORONTO--(BUSINESS WIRE)
FSD Pharma Inc. Announces Results of the Annual General and Special Meeting of Shareholders - Nominees of the Concerned Shareholders Elected to the Board of Directors TORONTO--(BUSINESS WIRE)--May 17, 2021--FSD Pharma Inc. (Nasdaq: HUGE) (CSE:HUGE) (FRA:0K9) (the "Company" or "F
Read more →QNTMFSD Pharma Announces Filing of Criminal Complaint Against Former Chief Financial Officer The Company knows on good authority that Mr. Anthony Durkacz, dissident Director/shareholder made unauthorized contact(s) with an i
FSD Pharma Announces Filing of Criminal Complaint Against Former Chief Financial Officer The Company knows on good authority that Mr. Anthony Durkacz, dissident Director/shareholder made unauthorized contact(s) with an intent to interfere with the company's banking relationships
Read more →QNTMFSD Pharma Announces Investigational New Animal Drug Filing With the FDA to Treat Dogs With Enteropathy The FDA has accepted the Investigational new Animal Drug application for review The proposed trial is expected to be
FSD Pharma Announces Investigational New Animal Drug Filing With the FDA to Treat Dogs With Enteropathy The FDA has accepted the Investigational new Animal Drug application for review The proposed trial is expected to be conducted at 5-10 sites in USA and will enroll up to 200
Read more →QNTMFSD Pharma Announces That ISS Recommends Shareholders Vote for the Company's Nominees to the Board Using Only the BLUE Proxy Shareholders URGED to Vote the BLUE proxy by 9:00 a.m. on
FSD Pharma Announces That ISS Recommends Shareholders Vote for the Company's Nominees to the Board Using Only the BLUE Proxy Shareholders URGED to Vote the BLUE proxy by 9:00 a.m. on May 12, 2021 TORONTO--(BUSINESS WIRE)--May 5, 2021--FSD Pharma Inc. (the "Company") today annou
Read more →QNTMFiled by newsfilecorp.com These materials are important and require your immediate attention. If you have any questions or require assistance in voting your shares, please contact the proxy solicitation agent, Gryphon Ad
These materials are important and require your immediate attention. If you have any questions or require assistance in voting your shares, please contact the proxy solicitation agent, Gryphon Advisors Inc. by telephone at 1.833.292.5847 toll-free in North America (1.416.902.5565
Read more →QNTMFSD Pharma Announces Appointment of Interim Chief Financial Officer TORONTO--(BUSINESS WIRE)
FSD Pharma Announces Appointment of Interim Chief Financial Officer TORONTO--(BUSINESS WIRE)--May 5, 2021--FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) (the "Company" or "FSD Pharma") is pleased to announce the appointment of Nathan Coyle, the Company's Corporate Controller as its I
Read more →QNTMFSD Pharma Issues Important Message to Shareholders and Response to Dissident Circular Management director nominees bring superior experience and expertise to drive positive growth, represent ALL shareholders interests a
FSD Pharma Issues Important Message to Shareholders and Response to Dissident Circular Management director nominees bring superior experience and expertise to drive positive growth, represent ALL shareholders interests and create value for ALL shareholders. Dissident shareholde
Read more →QNTMFSD Pharma Files Proxy Materials and Sends Letter to Shareholders Management director nominees bring superior experience and expertise to drive positive growth, represent ALL shareholders interests and create value for A
FSD Pharma Files Proxy Materials and Sends Letter to Shareholders Management director nominees bring superior experience and expertise to drive positive growth, represent ALL shareholders interests and create value for ALL FSD's COVID-19 FDA trials gaining momentum. Management
Read more →QNTMFSD Pharma Commences Proceedings Against Dissident Shareholders - Proceedings intended to appeal elements of Ontario Commercial List decision and challenge dissidents over material conflicts of interest and disclosure de
FSD Pharma Commences Proceedings Against Dissident Shareholders - Proceedings intended to appeal elements of Ontario Commercial List decision and challenge dissidents over material conflicts of interest and disclosure deficiencies - TORONTO--(BUSINESS WIRE)--March 31, 2021--FSD
Read more →QNTMFSD Pharma Enters into License Agreement to Develop FDA approved Veterinary Drugs for the Treatment of Gastro-Intestinal Diseases in Dogs and Cats -Announces Filing of Year-End 2020 Results and Provides Corporate Update
FSD Pharma Enters into License Agreement to Develop FDA approved Veterinary Drugs for the Treatment of Gastro-Intestinal Diseases in Dogs and Cats -Announces Filing of Year-End 2020 Results and Provides Corporate Update TORONTO--(BUSINESS WIRE)--March 16, 2021--FSD Pharma Inc.
Read more →QNTMFSD Pharma Announces US$20M At-The-Market Offering TORONTO--(BUSINESS WIRE)
FSD Pharma Announces US$20M At-The-Market Offering TORONTO--(BUSINESS WIRE)--February 11, 2021--FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) ("FSD Pharma" or the "Company") today announced that it has entered into an Equity Distribution Agreement dated February 11, 2021 (the "Sales
Read more →QNTMFiled by newsfilecorp.com EXECUTION VERSION FSD PHARMA INC. CLASS B
CLASS B SUBORDINATED VOTING SHARES EQUITY DISTRIBUTION AGREEMENT A.G.P./Alliance Global Partners 590 Madison Avenue, 36th Floor New York, New York 10022 Ladies and Gentlemen: FSD Pharma Inc., an Ontario corporation (the "Company"), confirms its agreement (this "Agreement")
Read more →QNTMFSD PHARMA INC. FORM 51-102F3 MATERIAL CHANGE REPORT 1. Name and Address of Company FSD Pharma Inc. (the " Corporation ") 100 King Street West, Suite 3400 Toronto, ON M5X 1A4 2. Date of Material Change
MATERIAL CHANGE REPORT FSD Pharma Inc. (the "Corporation") 100 King Street West, Suite 3400 A news release with respect to the material change referred to in this report was issued by the Corporation and disseminated on January 26, 2021 through Cision and filed on SEDAR at ww
Read more →QNTMFSD Provides Corporate Update TORONTO--(BUSINESS WIRE)
FSD Provides Corporate Update TORONTO--(BUSINESS WIRE)--January 26, 2021--FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) ("FSD Pharma" or the "Company") today announces the following corporate updates. The Company continues to pursue its strategy of completing a Phase 2 clinical tr
Read more →QNTMFSD Pharma Sets Date for Annual Meeting TORONTO--(BUSINESS WIRE)
FSD Pharma Sets Date for Annual Meeting TORONTO--(BUSINESS WIRE)--January 22, 2021--FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) ("FSD Pharma" or the "Company") today announced that it will hold its annual meeting of shareholders (the "Meeting") on June 29, 2021. The Meeting will a
Read more →QNTMFSD Pharma Announces First Patient Randomized in Phase 2 Trial of FSD201 for the Treatment of Hospitalized Patients with COVID-19 -----FDA has authorized randomized, controlled, double-blind study on 352 patients. The Co
FSD Pharma Announces First Patient Randomized in Phase 2 Trial of FSD201 for the Treatment of Hospitalized Patients with COVID-19 -----FDA has authorized randomized, controlled, double-blind study on 352 patients. The Company is expected to conduct this trial in 25-30 Medical Ce
Read more →QNTMFSD PHARMA INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS As used in this management's discussion and analysis of financial condition and results of operations ("MD&A"), unless
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF As used in this management's discussion and analysis of financial condition and results of operations ("MD&A"), unless the context indicates or requires otherwise, all references to the "Company", "FSD",
Read more →QNTMFiled by newsfilecorp.com FSD Pharma Announces Settlement of Class Action Proceeding TORONTO /
FSD Pharma Announces Settlement of Class Action Proceeding TORONTO / October 29, 2020 / FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) ("FSD Pharma" or the "Company") today announced that, subject to court certification and other customary conditions, it has entered into a definitive
Read more →QNTMFiled by newsfilecorp.com FSD Pharma Inc. Announces Closing of US$9.5 Million Registered Direct Offering TORONTO /
FSD Pharma Inc. Announces Closing of US$9.5 Million Registered Direct Offering TORONTO / October 21, 2020 / FSD Pharma Inc. (Nasdaq: HUGE) ("FSD Pharma" or the "Company"), today announced the closing of previously announced definitive agreements with investors for the purchase a
Read more →QNTMFiled by newsfilecorp.com FSD PHARMA INC. FORM 51-102F3 MATERIAL CHANGE REPORT 1. Name and Address of Company FSD Pharma Inc. (the " Corporation ") 100 King Street West, Suite 3400 Toronto, ON M5X 1A4 2. Date of Material
MATERIAL CHANGE REPORT 1. Name and Address of Company FSD Pharma Inc. (the "Corporation") 100 King Street West, Suite 3400 2. Date of Material Change A news release with respect to the material change referred to in this report was issued by the Corporation and disseminated
Read more →QNTMFiled by newsfilecorp.com FSD Pharma Inc. Announces US$9.5 Million Registered Direct Offering TORONTO /
FSD Pharma Inc. Announces US$9.5 Million Registered Direct Offering TORONTO / October 16, 2020 / FSD Pharma Inc. (Nasdaq: HUGE) ("FSD Pharma" or the "Company"), today announced that it has entered into definitive agreements with investors for the purchase and sale of 4,318,179 C
Read more →QNTMFiled by newsfilecorp.com FSD PHARMA INC. FORM 51-102F3 MATERIAL CHANGE REPORT 1. Name and Address of Company FSD Pharma Inc. (the " Corporation ") 520 William Street Cobourg, ON K9A 3A5 2. Date of Material Change
MATERIAL CHANGE REPORT 1. Name and Address of Company FSD Pharma Inc. (the "Corporation") 2. Date of Material Change A news release with respect to the material change referred to in this report was issued by the Corporation and disseminated on September 28, 2020, through ACC
Read more →QNTMFiled by newsfilecorp.com FSD Pharma Begins Phase 2 Clinical Trial to Evaluate FSD201 for the Treatment of Hospitalized COVID-19 Patients - FDA has authorized randomized, controlled, double-blind, multicenter study on 35
FSD Pharma Begins Phase 2 Clinical Trial to Evaluate FSD201 for the Treatment of Hospitalized COVID-19 Patients - FDA has authorized randomized, controlled, double-blind, multicenter study on 352 patients TORONTO (September 28, 2020) - FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE
Read more →QNTMFiled by newsfilecorp.com FSD Pharma Announces Phase 2 Clinical Trial IND Filing With The FDA to Treat Patients with COVID-19 - The study is expected to be conducted at 25-30 hospitals in North America - TORONTO (
FSD Pharma Announces Phase 2 Clinical Trial IND Filing With The FDA to Treat Patients with COVID-19 - The study is expected to be conducted at 25-30 hospitals in North America - TORONTO (August 31, 2020) - FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) ("FSD Pharma" or the "Com
Read more →QNTMFiled by newsfilecorp.com FSD PHARMA INC. ANNOUNCES CLOSING OF US$10 MILLION REGISTERED DIRECT OFFERING TO INSTITUTIONAL INVESTORS TORONTO (
FSD PHARMA INC. ANNOUNCES CLOSING OF US$10 MILLION REGISTERED DIRECT OFFERING TO INSTITUTIONAL INVESTORS TORONTO (August 6, 2020) FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) ("FSD Pharma" or the "Company") announces the closing of a previously announced agreement with investo
Read more →QNTMFiled by newsfilecorp.com FSD PHARMA INC. ANNOUNCES US$10 MILLION REGISTERED DIRECT OFFERING TORONTO (
FSD PHARMA INC. ANNOUNCES US$10 MILLION REGISTERED DIRECT OFFERING TORONTO (July 31, 2020) FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) ("FSD Pharma" or the "Company"), today announced that it has entered into definitive agreements with investors for the purchase and sale of 2,
Read more →QNTMFiled by newsfilecorp.com FSD Pharma Announces Decision to Surrender Health Canada Licenses for Subsidiary FV Pharma Inc. - FV Pharma to shut down operations within 30 days - TORONTO (
FSD Pharma Announces Decision to Surrender Health Canada Licenses for Subsidiary FV Pharma Inc. - FV Pharma to shut down operations within 30 days - TORONTO (July 30, 2020) - FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) ("FSD Pharma" or the "Company") today announc
Read more →QNTMFiled by newsfilecorp.com FSD Pharma Announces US$20M At-The-Market Offering TORONTO (
FSD Pharma Announces US$20M At-The-Market Offering TORONTO (July 13, 2020) - FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) ("FSD Pharma" or the "Company") today announced that it has entered into an Equity Distribution Agreement dated July 10, 2020 (the "Sales Agreement") with A
Read more →QNTMFiled by newsfilecorp.com FSD Pharma Reports Favorable Topline Results from Phase 1 First-in-Human Safety and Tolerability Study of Ultramicronized PEA All subjects completed the trial per protocol, no safety concerns fo
FSD Pharma Reports Favorable Topline Results from Phase 1 First-in-Human Safety and Tolerability Study of Ultramicronized PEA All subjects completed the trial per protocol, no safety concerns found up to the highest dose tested of 2400 mg/day TORONTO (June 22, 2020) - FSD Pha
Read more →QNTMFiled by newsfilecorp.com FSD PHARMA ANNOUNCES CLOSING OF C$10.125 MILLION PRIVATE PLACEMENT TO INSTITUTIONAL INVESTORS TORONTO (
FSD PHARMA ANNOUNCES CLOSING OF C$10.125 MILLION PRIVATE PLACEMENT TO INSTITUTIONAL INVESTORS TORONTO (June 9, 2020) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (the "Company") announces the closing of a previously announced private placement of 1,500,000 of the
Read more →QNTMFiled by newsfilecorp.com FSD PHARMA INC. ANNOUNCES C$10.125 MILLION PRIVATE PLACEMENT TORONTO /
FSD PHARMA INC. ANNOUNCES C$10.125 MILLION PRIVATE PLACEMENT TORONTO / June 4, 2020 / FSD Pharma Inc. (NASDAQ: HUGE) ("FSD Pharma" or the "Company"), today announced it has entered into definitive agreements with certain institutional investors for the purchase and sale of 1,500
Read more →QNTMFiled by newsfilecorp.com FSD PHARMA INC. FORM 51-102F3 MATERIAL CHANGE REPORT Item 1. Name and Address of Company FSD Pharma Inc. (the " Corporation ") 520 William Street Cobourg, ON K9A 3A5 Item 2. Date of Material Cha
FSD PHARMA INC. FORM 51-102F3 MATERIAL CHANGE REPORT Item 1. Name and Address of Company FSD Pharma Inc. (the " Corporation ") 520 William Street Cobourg, ON K9A 3A5 Item 2. Date of Material Change June 3, 2020 Item 3. News Release A news release with
Read more →QNTMFiled by newsfilecorp.com FSD Pharma Receives U.S. FDA Approval to design a Phase 2a Clinical Trial to Treat Patients with Suspected or Confirmed COVID-19 Diagnosis TORONTO (
FSD Pharma Receives U.S. FDA Approval to design a Phase 2a Clinical Trial to Treat Patients with Suspected or Confirmed COVID-19 Diagnosis TORONTO (June 3, 2020) - FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) ("FSD Pharma" or the "Company") today announced that the
Read more →QNTMFiled by newsfilecorp.com FSD Pharma Monetizes Non-Core Asset with Sale of Partial Equity Stake in Pharmadrug Inc. - Buyer Holds Option to Purchase Additional Shares - TORONTO (
FSD Pharma Monetizes Non-Core Asset with Sale of Partial Equity Stake in Pharmadrug Inc. - Buyer Holds Option to Purchase Additional Shares - TORONTO (May 21, 2020) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) ("FSD Pharma" or the "Company") today announced the
Read more →QNTMFiled by newsfilecorp.com FSD Pharma Takes Steps to Mitigate the Impact of COVID-19 on its Cannabis Production Facility in Cobourg, Ontario TORONTO (
FSD Pharma Takes Steps to Mitigate the Impact of COVID-19 on its Cannabis Production Facility in Cobourg, Ontario TORONTO (March 23, 2020) - FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) ("FSD Pharma" or the "Company") today announced that it has taken steps to mitig
Read more →QNTMFiled by newsfilecorp.com - 12 - - 13 - IN WITNESS WHEREOF , the parties have executed this Agreement affective as of the Effective Date. EPITECH GROUP SPA By: Signed by "Raffaella della Valle" Name: Raffaella della Vall
IN WITNESS WHEREOF, the parties have executed this Agreement affective as of the Effective Date. EPITECH GROUP SPA By: Signed by "Raffaella della Valle" Name: Raffaella della Valle Title: CEO FSD PHARMA INC By: Signed by "Raza Bokhari" Name: Raza Bokhari; MD Title: Chair
Read more →QNTMFiled by newsfilecorp.com FSD Pharma Begins Phase 1 In-human Safety and Tolerability Study of Ultra Micro-Palmitolylethanolamide (PEA) TORONTO (
FSD Pharma Begins Phase 1 In-human Safety and Tolerability Study of Ultra Micro-Palmitolylethanolamide (PEA) TORONTO (March 9, 2020) - FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company") today announced receipt of approval from the Ethics Commi
Read more →QNTMFiled by newsfilecorp.com FSD Pharma to Ring the Opening Bell of the Canadian Securities Exchange on Friday
FSD Pharma to Ring the Opening Bell of the Canadian Securities Exchange on Friday, March 6, 2020 - Reports audited financial results for the Fourth Quarter and Full Year ended December 31, 2019 - TORONTO (March 4, 2020) - FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (FRA: 0K9A)
Read more →QNTMFiled by newsfilecorp.com FSD Pharma Generates $7.7 Million in Proceeds and 670% Return on Investment through Sale of Interest in Cannara Biotech TORONTO
FSD Pharma Generates $7.7 Million in Proceeds and 670% Return on Investment through Sale of Interest in Cannara Biotech TORONTO, Feb. 20, 2020 /CNW/ - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company") today announced the sale of its 12% equit
Read more →QNTMFiled by newsfilecorp.com FSD Pharma and Solarvest Enhance Commitment to CBD Research Project TORONTO
FSD Pharma and Solarvest Enhance Commitment to CBD Research Project TORONTO, Feb. 4, 2020 /CNW/ - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma") and Solarvest BioEnergy Inc. (TSX-V: SVS) ("Solarvest") (collectively, the "Parties"), are pleased to announce
Read more →QNTMFiled by newsfilecorp.com Seasoned Healthcare Executive and Academic Luminary Larry Kaiser, MD, Joins FSD Pharma Board of Directors TORONTO
Seasoned Healthcare Executive and Academic Luminary Larry Kaiser, MD, Joins FSD Pharma Board of Directors TORONTO, Jan. 22, 2020 /CNW/ - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company") today announced that it has appointed Larry Kaiser, MD,
Read more →QNTMFiled by newsfilecorp.com FSD Pharma to Commence Trading on Nasdaq Capital Market Under Symbol 'HUGE' - Management to Present at Biotech Showcase 2020 - TORONTO
FSD Pharma to Commence Trading on Nasdaq Capital Market Under Symbol 'HUGE' - Management to Present at Biotech Showcase 2020 - TORONTO, Jan. 9, 2020 /CNW/ - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) ("FSD Pharma" or the "Company") announced that its Class B Subordi
Read more →Competitive Position
How QNTM ranks across every disease it competes inCompetitive Position is a premium feature
See how QNTM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial